Document:

exv10w2

 

Exhibit 10.2

RATIFICATION AND AMENDMENT AGREEMENT

(RELATING TO XO MERGER)

     This RATIFICATION AND AMENDMENT AGREEMENT (RELATING TO XO MERGER) (“Agreement”), dated
as of March 1, 2006, is delivered in connection with the Amended and Restated Credit and Guaranty
Agreement, dated as of January 16, 2003 (as amended and as it may be further amended, supplemented
or otherwise modified, the “Credit Agreement”; the terms defined therein and not otherwise
defined herein being used herein as therein defined), by and among XO COMMUNICATIONS, LLC, a
Delaware limited liability company, successor-by-merger to XO Communications, Inc., a Delaware
corporation (“XO LLC” or the “Company”), CERTAIN SUBSIDIARIES OF THE COMPANY, as
Guarantors, XO HOLDINGS, INC., a Delaware corporation, as a Guarantor (“XO Holdings”), LMDS
HOLDINGS, INC., a Delaware corporation, as a Guarantor (“LMDS”), and V&K Holdings, Inc., a
Delaware corporation, as a Guarantor (“V&K”),the Lenders party thereto from time to time
and, solely with respect to Section 6(b) hereof, MIZUHO CORPORATE BANK, LTD., as
administrative agent (“Administrative Agent”).

RECITALS

     A. Pursuant to Section 6.7(b) (Fundamental Changes; Disposition of Assets;
Acquisitions) of the Credit Agreement, the Company or any of its Subsidiaries may consolidate with
or merge with or into or sell, assign, convey, lease or transfer all or substantially all of its
properties and assets if (i) the Company or such Subsidiary shall be the continuing Person, or the
resulting, surviving or transferee Person (the “surviving entity”) shall be a Person organized and
existing under the laws of the United States or any State thereof or the District of Columbia; and
(ii) the surviving entity (other than an existing Guarantor) shall expressly assume, pursuant to
documentation delivered to the Administrative Agent and Requisite Lenders, all of the obligations
of the Company or such Subsidiary, as applicable under the Credit Documents, and the Company or the
surviving entity shall have taken all steps necessary to perfect and protect the security interests
granted or purported to be granted by the Collateral Documents in the applicable Collateral.

     B. On the date hereof, XO LLC became the successor-by-merger to XO Communications, Inc.
(“XO Inc.”), with XO LLC continuing as the surviving entity (such merger, the “XO
Merger”).

     C. XO LLC desires to confirm that by virtue of the XO Merger, XO LLC assumed the Obligations,
covenants, agreements and commitments of XO Inc. as the “Company” under the Credit Agreement and
the other Credit Documents.

     D. Each of XO Holdings, LMDS and V&K desires to reaffirm its status as a Credit Party and
Guarantor of the Company’s Obligations under the Credit Agreement notwithstanding the fact that, by
virtue of the XO Merger and the transactions contemplated thereby, it is no longer a Domestic
Subsidiary of the Company.

     E. The Credit Agreement contains many references to “Subsidiaries” and “Domestic Subsidiaries”
and the parties intend that such references shall continue to apply to XO Holdings,

 

 

LMDS and V&K notwithstanding the fact that, by virtue of the XO Merger and the transactions
contemplated thereby, they are no longer Domestic Subsidiaries of the Company.

     F. XO Inc., XO Holdings and Elk Associates, LLC (“Elk”) are parties to that certain
Equity Purchase Agreement, dated as of November 4, 2005, as amended on March 1, 2006, in the form
attached hereto as Exhibit 1 (as further amended from time to time, the “Equity
Purchase Agreement”; and together with any and all related schedules, exhibits, documents,
agreements, instruments and side letters, which are also attached hereto as Exhibit 1, the
“Equity Purchase Documents”), providing for the sale by XO Holdings to Elk of all of the
issued and outstanding membership interests of XO LLC (the “Sale Transaction”). In
contemplation of the closing of the Sale Transaction pursuant to the Equity Purchase Agreement, XO
Holdings has asked the Requisite Lenders to confirm that upon satisfaction of the Release
Conditions (as defined below), the Requisite Lenders shall direct the Administrative Agent to
irrevocably release and discharge, and shall otherwise take such actions as shall be necessary to
cause to be irrevocably released and discharged, each of XO Holdings, LMDS and V&K from any and all
Obligations, and from any and all covenants, agreements, commitments, obligations and encumbrances,
under the Credit Agreement and other Credit Documents, and to provide any and all releases and
terminations necessary to terminate any and all liens and security interests and all evidence
thereof, including, without limitation, all financing statements filed by or on behalf of
Administrative Agent against each of XO Holdings, LMDS and V&K and their respective assets.

     G. The Company and the Credit Parties have agreed with Requisite Lenders that, in connection
with the XO Merger and the transactions contemplated thereby, certain provisions of the Credit
Agreement shall be amended as provided herein.

     H. The Lenders executing this Agreement constitute the Requisite Lenders pursuant to
Section 1.1 of the Credit Agreement.

     NOW, THEREFORE, in consideration of the terms and conditions, premises and the other mutual
covenants contained herein, and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree as follows:

AGREEMENT

     1. Accuracy of Recitals. Each of the undersigned (other than the Administrative
Agent) hereby acknowledges and agrees that the foregoing Recitals are true and accurate and are
incorporated herein by reference.

     2. Representations and Warranties. In order to induce the Administrative Agent and
Requisite Lenders to enter into this Agreement, each Credit Party hereby represents and warrants to
Administrative Agent and Requisite Lenders as follows as of the date hereof:

          (a) it is duly organized, validly existing and in good standing under the laws of its
jurisdiction of organization;

          (b) the execution, delivery and performance by it of the XO Merger, the XO Merger Documents,
this Agreement and the other Credit Documents to which it is a party or is bound are within its
powers, have been duly authorized, and do not and will not (i) violate any

2

 

provisions of any law or any governmental rule or regulation applicable to the Company, any of
its Subsidiaries or any other Credit Party, any of the Organizational Documents of Company, of any
of its Subsidiaries or of any other Credit Party, or any order, judgment or decree of any court or
other agency of government binding on Company, on any of its Subsidiaries or on any other Credit
Party, except for any such violation of law or governmental rule or regulation or any such order,
judgment or decree that would not reasonably be expected to have a Material Adverse Effect; (ii)
breach or constitute (with due notice or lapse of time or both) a default under any Contractual
Obligation of Company, of any of its Subsidiaries or of any other Credit Party, except for any such
default that would not reasonably be expected to have a Material Adverse Effect; (iii) result in or
require the creation or imposition of any Lien upon any of the properties or assets of Company, of
any of its Subsidiaries or of any other Credit Party (other than Liens created under any of the
Credit Documents in favor of Administrative Agent, on behalf of Lenders); or (iv) require any
approval of stockholders or any approval or consent of any Person under any Contractual Obligation
of Company, of any of its Subsidiaries or of any other Credit Party, which, in either case, has not
been obtained, except for any such approval or consent of any such Person under any such
Contractual Obligation that would not reasonably be expected to have a Material Adverse Effect;

          (c) (i) the execution, delivery and performance of this Agreement has been duly authorized by
all necessary action on the part of such Credit Party; (ii) no agreement, license, permit,
approval, authorization, registration, order, declaration or filing with any Governmental Authority
or body or any other Person is required in connection with the execution, delivery, performance,
validity or enforceability of this Agreement by or against it, except for any such agreement that
the failure of which to enter into, or any such license, permit, approval, authorization,
registration, order, declaration or filing that the failure of which to obtain or make, would not
reasonably be expected to have a Material Adverse Effect; and (iii) this Agreement constitutes its
legal, valid and binding obligation enforceable against it in accordance with its terms, except as
enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting the enforcement of creditors’ rights generally or by equitable principles
relating to enforceability;

          (d) the XO Merger was permitted under Section 6.7(b) of the Credit Agreement;

          (e) no agreement, license, permit, approval, authorization, registration, order, declaration
or filing with any Governmental Authority or body or any other Person was required for or in
connection with the XO Merger, except for any of the foregoing which were obtained or made by
Company or its Subsidiaries, as applicable, and those that the failure of which to obtain or make
would not reasonably be expected to have a Material Adverse Effect;

          (f) after giving effect to this Agreement, it is in compliance with all covenants and
agreements in the Credit Documents and it is not in default under the Credit Agreement or any other
Credit Document and no Default or Event of Default exists, has occurred and is continuing or would
result by the execution, delivery or performance of this Agreement, except in each case any default
under, or noncompliance with the terms of, the Credit Agreement waived pursuant to Section 10.5 of
the Credit Agreement; and

3

 

          (g) after giving effect to this Agreement, the representations and warranties contained in the
Credit Documents are true and correct in all material respects as of the date hereof as if made on
such date, except to the extent such representations or warranties relate solely to an earlier date
(in which case such representations and warranties were true on and as of such date).

     3. Confirmation of Assumption of Obligations. XO LLC hereby absolutely and
unconditionally confirms, by virtue of the XO Merger, its assumption and agreement to pay, perform
and discharge when due all Obligations, covenants, agreements and commitments of Company under the
Credit Agreement and other Credit Documents, whether now existing or hereafter arising, under the
Credit Agreement or other Credit Documents, in each case in accordance with the terms and
conditions thereof. XO LLC hereby confirms that, by virtue of the XO Merger and subject to the
terms hereof, it has become subject to all terms, conditions, representations, covenants and other
provisions set forth in the Credit Agreement and the other Credit Documents made or pertaining to
“Company” thereunder as provided in the Credit Agreement and the other Credit Documents.

     4. Confirmation of Status as Credit Party and Guarantor; Agreement to be Bound by
Subsidiary Provisions. Each of XO Holdings, LMDS and V&K hereby absolutely and unconditionally
confirms that it is and shall continue to be a “Guarantor” and “Credit Party” under and pursuant to
the terms and provisions set forth in the Credit Agreement and the other Credit Documents
notwithstanding the fact that, by virtue of the XO Merger, it is no longer a Domestic Subsidiary of
the Company. Each of XO Holdings, LMDS and V&K hereby absolutely and unconditionally agrees that,
subject to the terms hereof, it shall continue to be subject to and be bound by all agreements,
covenants, representations and warranties applicable to Subsidiaries and/or Domestic Subsidiaries
under the Credit Agreement and other Credit Documents notwithstanding the fact that, by virtue of
the XO Merger, it is no longer a Domestic Subsidiary of the Company, in each case as provided in
the Credit Agreement and the other Credit Documents. Each of XO Holdings, LMDS and V&K hereby
confirms its grant to Secured Party (as defined in the Pledge and Security Agreement) of a security
interest in all of its right, title and interest in and to all Collateral to secure the Secured
Obligations (as defined in the Pledge and Security Agreement), in each case whether now or
hereafter existing or in which it now has or hereafter acquires an interest and wherever the same
may be located, and in each case as provided in the Pledge and Security Agreement. XO Holdings
further confirms its pledge to Secured Party (as defined in the Pledge and Security Agreement) of
all of its right, title and interest in and to its Subsidiaries, including, without limitation, in
and to all capital stock, equity securities, membership interests, ownership interests and items
comprising Pledged Equity Interests (as defined in the Pledge and Security Agreement), as
applicable, of Company, LMDS, and V&K, owned or held of record or beneficially by XO Holdings, and
confirms that such interests constitute “Pledged Equity Interests” (as defined in the Pledge and
Security Agreement) under the Pledge and Security Agreement, in each case as provided in the Pledge
and Security Agreement.

4

 

     5. Acknowledgement of Obligations.

          (a) Each Credit Party hereby acknowledges and agrees that it is unconditionally liable to the
Administrative Agent and Lenders for the full payment of all of the Obligations including, without
limitation, those Obligations as of the date hereof set forth on Schedule A attached hereto
and incorporated herein by reference, plus all interest, charges, fees, costs, and expenses that
are payable under and pursuant to the terms of the Credit Agreement and other Credit Documents.

          (b) Each Credit Party hereby acknowledges, confirms and agrees that the Administrative Agent
and Lenders have and have had a valid, enforceable and perfected first priority security interest
and Lien upon all of the Collateral granted by Credit Parties to Administrative Agent and/or
Lenders pursuant to the Credit Agreement and Credit Documents to secure the Obligations, subject
only to Permitted Liens. In furtherance and not in limitation of any Credit Document, each Credit
Party grants or reaffirms its grant, as the case may be, pledges and assigns to Administrative
Agent and Lenders a continuing security interest and Lien upon the Collateral, in each case as
provided in the Credit Agreement and the other Credit Documents.

     6. Sale Transaction.

     (a) In consideration of the agreements and commitments of the Company and the other Credit
Parties hereunder, Requisite Lenders hereby agree that upon the date that the Release Conditions
are satisfied, the Requisite Lenders shall direct and instruct the Administrative Agent in writing,
and shall otherwise take such actions as shall be necessary, to: (i) irrevocably release and
discharge each of XO Holdings, LMDS and V&K from any and all Obligations, and from any and all
covenants, agreements, commitments, obligations and encumbrances, under the Credit Agreement and
the other Credit Documents; and (ii) terminate, at the sole cost and expense of Company and the
other Credit Parties (which costs and expenses shall be reasonable and documented), and provide all
releases and terminations necessary to terminate any and all liens and security interests and all
evidence thereof, including, without limitation, all financing statements filed by or on behalf of
Administrative Agent against each of XO Holdings, LMDS and V&K and their respective assets.

     (b) The undersigned Requisite Lenders: (i) hereby instruct the Administrative Agent to
acknowledge and agree to this Section 6(b); and (ii) (A)(I) acknowledge and agree that the
Administrative Agent shall be entitled to rely upon the direction and instruction to be provided to
the Administrative Agent by the Requisite Lenders pursuant to clause (a) above when
providing the terminations and releases referenced therein, and (II) represent and warrant that
such direction and instruction does not, and when such direction and instruction is actually
provided by the Requisite Lenders to Administrative Agent will not, be an instruction or direction
to the Administrative Agent requiring the instruction or direction of any Lenders other than the
Requisite Lenders pursuant Section 10.5 of the Credit Agreement or otherwise, and (B) agree
to jointly and severally indemnify Administrative Agent, to the extent that Administrative Agent
shall not have been reimbursed by any Credit Party in accordance with the Credit Agreement and the
other Credit Documents, for and against any and all liabilities, obligations, losses, damages,
penalties, actions, judgments, suits, costs, expenses (including counsel fees and disbursements) or
disbursements of any kind or nature whatsoever which may be imposed on, incurred by or

5

 

asserted against Administrative Agent in connection with Administrative Agent’s acknowledging and
agreeing to this Section 6(b) or providing any such terminations or releases;
provided, however, that no Requisite Lender or Credit Party shall be liable for any
portion of such liabilities, obligations, losses, damages, penalties, actions, judgments, suits,
costs, expenses or disbursements resulting from Administrative Agent’s gross negligence or willful
misconduct. In reliance of the foregoing sentence, Administrative Agent agrees to provide the
releases and terminations referenced in clause (a) above when so directed by the Requisite
Lenders and the Requisite Lenders and the Credit Parties acknowledge and agree that neither the
Administrative Agent’s acknowledgement and agreement to this Section 6(b) nor the
Administrative Agent providing such terminations or releases shall constitute gross negligence or
willful misconduct.

     (c) For purposes of this Agreement the term “Release Conditions” shall mean
satisfaction of all of the following conditions to the Requisite Lenders’ reasonable satisfaction:
(i) any modifications to the versions of the Equity Purchase Documents attached hereto as
Exhibit 1 shall have been delivered to Administrative Agent and Requisite Lenders and all
material modifications thereto shall have been approved by Requisite Lenders in their reasonable
discretion; (ii) concurrently with the closing of the Sale Transaction, XO Holdings shall deliver
or cause to be delivered to Administrative Agent (for the benefit of the Lenders) an indefeasible
payment in an amount equal to the outstanding principal amount of the Term Loans on and as of such
date, together with all accrued interest thereon (such amount shall be calculated by Administrative
Agent, and such calculation shall be conclusive and binding on Company, the Credit Parties and each
Lender, absent manifest error) less $75,000,000.00 for application as a permanent reduction
of the Term Loans in accordance with Section 2.13 (Application of Prepayments/Reductions)
of the Credit Agreement; (iii) there shall be no Default or Event of Default under the Credit
Agreement or other Credit Documents other than any Default or Event of Default waived in accordance
with Section 10.5 of the Credit Agreement; and (iv) the Credit Parties shall have executed
and delivered to Administrative Agent and Requisite Lenders all other agreements, documents,
instruments, schedules, exhibits and certificates as the Administrative Agent and Requisite Lenders
shall reasonably require in connection therewith, all in form and substance reasonably satisfactory
to Requisite Lenders.

     7. Amendments. The Credit Parties and Requisite Lenders agree that the Credit
Agreement and the other Credit Documents are hereby amended as follows:

          (a) Company. Each reference in the Credit Agreement and other Credit Documents to
“Company” means “XO Communications, LLC” and any other Person that at any time after the date
hereof becomes “Company” in accordance with the terms and conditions set forth in the Credit
Agreement.

          (b) XO Communications, Inc. 

	 	(i)	 	Each reference in the Credit Agreement to “XO
Communications, Inc., a Delaware corporation” is deleted in the
entirety and replaced with the following:
	 
	 	 	 	“XO Communications, LLC, a Delaware limited liability company
(successor-by-merger to XO Communications, Inc.).”

6

 

	 	(ii)	 	Each reference in the Credit Agreement to “XO
Communications, Inc.” is deleted in the entirety and replaced with the
following:
	 
	 	 	 	“XO Communications, LLC”.

          (c) Guarantor Provisions.

	 	(i)	 	Section 1 (Definitions and
Interpretations) of the Credit Agreement is amended to delete the
definition of “Guarantor” in the entirety and to replace it with the
following:
	 
	 	 	 	“Guarantor” means XO Holdings, Inc., a Delaware corporation,
LMDS Holdings, Inc., a Delaware corporation, V&K Holdings, Inc., a
Delaware corporation, and each wholly-owned Domestic Subsidiary of
the Company.
	 
	 	(ii)	 	Each other reference in the Credit Agreement
and other Credit Documents to “Guarantor” shall mean XO Holdings, Inc.,
a Delaware corporation, LMDS Holdings, Inc., a Delaware corporation,
V&K Holdings, Inc., a Delaware corporation, and each Domestic
Subsidiary of Company.

          (d) Subsidiary Provisions. Each of XO Holdings, LMDS and V&K hereby absolutely and
unconditionally agrees that, except as provided on Exhibit 7(d)(i) attached hereto, it
shall continue to be subject to and be bound by all agreements, covenants, representations and
warranties applicable to Subsidiaries and/or Domestic Subsidiaries under the Credit Agreement and
other Credit Documents notwithstanding the fact that, by virtue of the XO Merger, it is no longer a
Domestic Subsidiary of the Company. By way of example only, the Sections of the Credit Agreement
that are listed on Exhibit 7(d)(ii) attached hereto shall continue to apply to XO Holdings,
LMDS, V&K and their respective Subsidiaries notwithstanding any language therein that purports to
limit such Sections to “Subsidiaries” or “Domestic Subsidiaries” of Company. However, the Sections
of the Credit Agreement listed on Exhibit 7(d)(i) attached hereto shall no longer be
applicable to XO Holdings and LMDS.

          (e) Definitions. Section 1.1 (Definitions) of the Credit Agreement is amended
as follows:

	 	(i)	 	To delete subsection (ii) of the
definition of “Investment” in the entirety and to replace it
with the following:

“(ii) any direct or indirect redemption, retirement, purchase or other
acquisition for value, by any Subsidiary of Company from any Person (other
than, in the case of any such action by Company and the Guarantors, from any
Guarantor or any person who becomes a Guarantor in connection with such
Investment) of any Capital Stock of such Person, other than any direct or
indirect redemption contemplated by the XO Merger Agreement;”

7

 

	 	(ii)	 	to delete the definition of “Significant
Subsidiary” therein and to replace it with the following:

“Significant Subsidiary” means a Subsidiary, i.e., a “restricted
subsidiary”, that is a “significant subsidiary” as defined in Rule 1-02(w)
of Regulation S-X or is otherwise designated a Significant Subsidiary by
Company or XO Holdings; provided that the relevant percentage of
consolidated revenues, consolidated assets and consolidated net income of
Company, XO Holdings and their respective Subsidiaries which are measured
for purposes of this definition shall be 1%, and not as otherwise specified
in such Rule.

          (f) Additional Definitions. Section 1.1 (Definitions) of the Credit Agreement
is amended to add the following definitions in the appropriate alphabetical order:

	 	(i)	 	“Equity Purchase Agreement” shall mean
the Equity Purchase Agreement dated as of November 4, 2005, as amended
on March 1, 2006, by and among XO Holdings, Inc., as Seller, XO Inc.,
as Company and Elk Associates LLC, as Buyer, in the form of Exhibit
1 to the Ratification Agreement (as further amended from time to
time).
	 
	 	(ii)	 	“Ratification Agreement” shall mean the
Ratification and Amendment Agreement (Relating to XO Merger) dated as
of March 1, 2006 by and among Company, certain Subsidiaries of Company,
as Guarantors, XO Holdings Inc., as a Guarantor, LMDS Holdings, Inc.,
as a Guarantor and, solely with respect to Section 6(b) thereof, the
Administrative Agent.
	 
	 	(iii)	 	“XO Inc.” shall mean XO
Communications, Inc., as such entity existed prior to the consummation
of the XO Merger.
	 
	 	(iv)	 	“XO LLC” shall mean XO Communications,
LLC, successor-by-merger to XO Inc.
	 
	 	(v)	 	“XO Merger” shall have the meaning
given such term in the Ratification Agreement.
	 
	 	(vi)	 	“XO Merger Agreement” shall mean that
certain Agreement and Plan of Merger, dated as of February 28, 2006
among XO Inc., XO LLC and XO Holdings, Inc., without regard to any
amendments thereto.
	 
	 	(vii)	 	“XO Merger Documents” shall mean the
XO Merger Agreement and all of the agreements, documents and
instruments executed and delivered pursuant to the terms thereof,
together with all

8

 

	 	 	 	schedules, exhibits, annexes, amendments, supplements or
modifications thereto.

          (g) Disclosure. Section 4.25 (Disclosure) of the Credit Agreement is amended
to add the following in between the first and second sentences therein.

“Credit Parties shall deliver to Administrative Agent (with sufficient copies for
all of the Lenders) true and correct copies of all XO Merger Documents. No XO
Merger Document furnished to Administrative Agent by or on behalf of any Credit
Party, nor any representation or warranty made by any Credit Party in any XO Merger
Document, contains any untrue statement of material fact or omits to state a
material fact (known to such Credit Party or any of its Subsidiaries, in the case of
any document not furnished by either of them) necessary in order to make the
statements contained herein or therein not misleading in light of the circumstances
in which the same were made.”

          (h) Subsidiaries. Section 5.9 (Subsidiaries) is deleted in the entirety and replaced
with the following:

“5.9 Subsidiaries. In the event that any Person becomes a Domestic Subsidiary of
Company, or any other Credit Party, then Company or such Credit Party, as applicable, shall
(a) promptly cause such Domestic Subsidiary to become a Guarantor hereunder and a Grantor
under the Pledge and Security Agreement by executing and delivering to Administrative Agent
a Counterpart Agreement, and (b) take all such actions and execute and deliver, or cause to
be executed and delivered, all such documents, instruments, agreements, and certificates as
are similar to those described in Sections 3.1(b) and 3.1(f); provided that the actions
specified in the foregoing clauses (a) and (b) of this sentence shall not be required for
(1) those Subsidiaries where Company or the applicable Credit Party has acquired less than
100%, but at least 80% of, the Capital Stock of such Subsidiary, until such time as any such
Subsidiary becomes a wholly owned Subsidiary of Company or such Credit Party, as applicable
or (2) any Person that becomes a Domestic Subsidiary of Company or any other Credit Party
after the date hereof if and to the extent and for so long as such Person’s Guaranty of the
Obligations or grant of Liens under the Pledge and Security Agreement would violate
applicable law or constitute a default under the terms of any Acquired Debt of such Person
or would obligate it pursuant to the terms of such Acquired Debt to guarantee or secure any
Indebtedness other than the Term Loans, unless Administrative Agent requests and otherwise
consents to the issuance of a guarantee or the granting of Liens in respect of such
Indebtedness, it being understood that the actions specified in the foregoing clauses (a)
and (b) of this sentence will be taken at the earliest time and to the full extent they do
not violate applicable law or constitute a default under such Acquired Debt or obligate it
to guarantee or secure such other Indebtedness. In the event that any Person becomes a
Foreign Subsidiary of Company or any other Credit Party, and the ownership interests of such
Foreign Subsidiary are owned by Company, by any Domestic Subsidiary thereof or by any other
Credit Party, subject to applicable law, Company shall, or shall cause such Domestic
Subsidiary or such other Credit Party to, deliver, all such documents, instruments,
agreements, and certificates as are similar to those described in Section

9

 

3.1(b), and take all of the actions necessary to grant and to perfect a First Priority Lien
in favor of Administrative Agent, for the benefit of Lenders, under the Pledge and Security
Agreement in such ownership interests; provided that no more than 65% of the Capital Stock
of such Foreign Subsidiary shall be subject to the provisions of this Section 5.9 and
provided further that such Foreign Subsidiary shall be a first tier Foreign Subsidiary of
Company or a Domestic Subsidiary or a Credit Party. With respect to each such Subsidiary,
Company shall promptly send to Administrative Agent written notice setting forth with
respect to such Person (i) the date on which such Person became a Subsidiary of Company, of
any Domestic Subsidiary or any Credit Party, and (ii) all of the data required to be set
forth in Schedules 4.1 and 4.2 with respect to all Subsidiaries of Company, its Domestic
Subsidiaries and the other Credit Parties; provided, such written notice shall be deemed to
supplement Schedules 4.1 and 4.2 for all purposes hereof.”

          (i) Restricted Payments; Restrictions on Subsidiary Distributions. Section
6.4 (Restricted Payments; Restrictions on Subsidiary Distributions) is amended as follows:

	 	(i)	 	to amend subsection (a) therein to add
the following after the end of subsection (iii) therein:

“(iv) Company and its Subsidiaries may make Restricted Junior Payments to
the extent contemplated by the terms and provisions of the XO Merger
Agreement”.

	 	(ii)	 	to delete subsection (b) therein in the
entirety and replace it with the following:

“(b) Except as provided herein, no Credit Party shall, nor shall it permit
any of its Subsidiaries to, create or otherwise cause or suffer to exist or
become effective any consensual encumbrance or restriction of any kind on
the ability of any Subsidiary of Company to (i) pay dividends or make any
other distributions on any of such Subsidiary’s Capital Stock owned by
Company or any other Subsidiary of Company (other than any consensual
restriction set forth in Section 6.2(c) of the Equity Purchase Agreement),
(ii) repay or prepay any Indebtedness owed by such Subsidiary to Company or
any other Subsidiary of Company (other than any consensual restriction set
forth in Section 6.2(i) of the Equity Purchase Agreement), (iii) make loans
or advances to Company or any other Subsidiary of Company, or (iv) transfer
any of its property or assets to Company or any other Subsidiary of Company
other than restrictions (1) in agreements evidencing or securing
Indebtedness of Subsidiaries permitted hereunder, (2) by reason of customary
provisions restricting assignments, subletting or other transfers contained
in leases, licenses, joint venture agreements and similar agreements entered
into in the ordinary course of business, and (3) that are or were created by
virtue of any transfer of, agreement to transfer or option or right with
respect to any property, assets or Capital Stock not otherwise prohibited
under this Agreement.”

10

 

          (j) Fundamental Changes. Section 6.7 (Fundamental Changes; Disposition of
Assets; Acquisitions) of the Credit Agreement is amended to delete the period at the end thereof
and to replace it with the following:

“; and (k) the conversion or exchange of securities and the assignment and/or
assumption of certain rights and obligations contemplated by the terms and
provisions of the XO Merger Agreement.”

          (k) Amendments to XO Merger Documents. Section 6.11 (Amendments or Waivers of
Indebtedness or Restructuring Transaction Documents) of the Credit Agreement is amended:

	 	(i)	 	to delete the title “Amendments or Waivers of
Indebtedness or Restructuring Transaction Documents” therein and to
replace it with the following “Amendments or Waivers of Indebtedness or
Restructuring Transaction Documents or XO Merger Documents”; and
	 
	 	(ii)	 	to delete subsection (b) therein in the
entirety and replace it with the following:
	 
	 	 	 	“No Credit Party shall nor shall it permit any of its Subsidiaries
to, agree to any amendment, restatement, supplement or other
modification to, or waiver of, any term or provision of or any of its
rights under any Restructuring Transaction Document (other than: (i)
the Organizational Documents of such Credit Party; (ii) the
amendments, restatements, supplements, modifications, or waivers
relating to the Management Incentive Plan, the Management Options,
the Management Retention Bonus Plan that have been approved by the
board of directors of the Company; and (iii) the modifications
thereof that are required to comply with the terms and provisions set
forth in Section 2.5 of the XO Merger Agreement) without in each case
obtaining the prior written consent of Requisite Lenders to such
amendment, restatement, supplement or other modification or waiver.”
	 
	 	(iii)	 	to add a new subsection (c) after the
end of subsection (b) therein as follows:
	 
	 	 	 	“(c) No Credit Party shall, nor shall it permit any of its
Subsidiaries to, agree to any amendment, restatement, supplement or
other modification to, or waiver of, any term or provision of or any
of its rights under any XO Merger Document in any manner that would
be materially adverse to Administrative Agent or any Lender (other
than, subject to the terms and provisions of this Agreement, the
Organizational Documents of such Credit Party) without in each case
obtaining the prior written consent of

11

 

	 	 	 	Requisite Lenders to such amendment, restatement, supplement or other
modification or waiver.”

          (l) Significant Subsidiaries. Section 6.13 (Significant Subsidiaries) is
deleted in the entirety and replaced with the following:

“6.13 Significant Subsidiaries. At no time will those Subsidiaries of Company
or XO Holdings which are not Significant Subsidiaries account for more than 10% or more of
the consolidated net income, consolidated revenues or consolidated assets, in each case as
specified in Rule 1-02(w) of Regulation S-X, of Company, XO Holdings and their respective
Subsidiaries.”

     8. Conditions Precedent. This Agreement shall be effective upon satisfaction of the
following conditions to Requisite Lenders’ satisfaction:

          (a) the Requisite Lenders shall have received the countersignatures of the Company and the
other Credit Parties to this Agreement evidencing their agreement to the terms and provisions
hereof;

          (b) the Requisite Lenders shall have received true, accurate and complete executed copies of
the schedules, exhibits and documents attached hereto;

          (c) the Requisite Lenders shall have received evidence that the execution, delivery and
performance of this Agreement by the Credit Parties has been duly authorized by all necessary
corporate or limited liability company action, as appropriate;

          (d) the XO Merger shall have occurred, and the Company shall have delivered, or caused to be
delivered, to Administrative Agent and Requisite Lenders: (i) a true, correct and complete
executed (where applicable) copy of each of the XO Merger Documents, together with all exhibits and
schedules thereto; and (ii) evidence that the XO Merger Documents have been filed with the
applicable Governmental Authorities and that the XO Merger is valid and effective in accordance
with the terms and provisions of the XO Merger Documents and applicable corporate statutes;

          (e) XO Holdings and LMDS shall have pledged or reconfirmed their pledge, as the case may be,
to Administrative Agent of their ownership in each of their Subsidiaries in accordance with
Section 4 of this Agreement;

          (f) the Administrative Agent shall have received payment of all outstanding reasonable and
documented fees and expenses owing to Administrative Agent by the Credit Parties;

          (g) there shall be no Default or Event of Default under the Credit Agreement or other Credit
Documents other than Defaults or Events of Default waived in accordance with Section 10.5
of the Credit Agreement; and

          (h) the Credit Parties shall have executed and delivered to Administrative Agent and Requisite
Lenders all other documents, instruments, schedules, exhibits and

12

 

certificates as the Requisite Lenders shall reasonably require in connection herewith, all in
form and substance reasonably satisfactory to the Requisite Lenders.

     9. Additional Covenants. In addition to and not in lieu of the covenants set forth in
the Credit Agreement, the Credit Parties hereby covenant and agree that they shall satisfy and
perform the following covenants to the Requisite Lenders’ satisfaction on or before the dates set
forth below, provided that any failure by the Credit Parties to fully and timely satisfy any of the
conditions set forth below, if such failure shall continue for ten (10) days following written
notice of such failure to Company by the Requisite Lenders or Administrative Agent issued at the
request of Requisite Lenders, shall constitute an Event of Default:

          (a) on or before April 30, 2006, the Credit Parties shall deliver to Administrative Agent and
Requisite Lenders updated insurance certificates naming the Administrative Agent and Lenders as
loss payee and additional insured, as applicable;

          (b) on or before April 30, 2006, the Credit Parties shall have duly executed and delivered to
Administrative Agent and Requisite Lenders amendments to control agreements to evidence the change
in the customer as a result of the XO Merger;

          (c) on or before April 30, 2006, the Company: (i) shall be registered with the appropriate
Governmental Authorities as the owner of all Intellectual Property transferred to Company pursuant
to the XO Merger Documents; and (ii) shall execute and deliver to Administrative Agent all
amendments, reasonably requested by Requisite Lenders, to any and all filings that Administrative
Agent has on record at the United States Patent and Trademark Office and/or United States Copyright
Office, as applicable, with respect to Intellectual Property that was transferred to Company
pursuant to the XO Merger, in each case to evidence the change in owner as a result thereof;

          (d) on or before April 30, 2006, Company shall deliver to Administrative Agent and Requisite
Lenders a good standing certificate from the applicable Governmental Authority of Company’s
jurisdiction of formation and from each jurisdiction in which is Company qualified as a foreign
corporation or other entity to do business;

          (e) on or before April 30, 2006, the Credit Parties shall have delivered to Administrative
Agent and Requisite Lenders supplements to Schedules 4.1 (General Information),
4.2 (Location of Equipment and Inventory), 4.4 (Investment Related Property),
4.5 (Material Contracts), 4.6 (Description of Letters of Credit), 4.7
(Intellectual Property) and 4.8 (Commercial Tort Claims) to the Pledge and Security
Agreement, which supplements shall be in form and content reasonably satisfactory to the Requisite
Lenders and shall be attached hereto as Exhibit 9(e); and

          (f) on or before April 30, 2006, the Credit Parties shall deliver to Administrative Agent and
Requisite Lenders amended and restated disclosure schedules to the Credit Agreement and Pledge and
Security Agreement, which shall be in form and content reasonably satisfactory to the Requisite
Lenders and shall be attached hereto as Exhibit 9(f) (collectively, the “Amended and
Restated Disclosure Schedules”).

13

 

     10. Miscellaneous.

          (a) The execution, delivery and effectiveness of this Agreement shall not, except as expressly
provided herein, be deemed to be an amendment or modification of, or operate as a waiver of, any
provision of the Credit Agreement or any other Credit Document or any right, power or remedy of
Administrative Agent, nor constitute a waiver of any provision of the Credit Agreement or any other
Credit Document, or any other document, instrument and/or agreement executed or delivered in
connection therewith or of any Default or Event of Default under any of the foregoing, in each case
whether arising before or after the date hereof or as a result of performance hereunder or
thereunder. This Agreement shall not preclude the future exercise of any right, remedy, power or
privilege available to Administrative Agent whether under the Credit Agreement, other Credit
Documents, at law or otherwise.

          (b) This Agreement may be executed in any number of counterparts (including by facsimile), and
by the different parties hereto or thereto on the same or separate counterparts, each of which
shall be deemed to be an original instrument but all of which together shall constitute one and the
same agreement. Each party agrees that it will be bound by its own facsimile signature and that it
accepts the facsimile signature of each other party. The Credit Parties shall provide original
signed copies of all Credit Documents. The descriptive headings of the various sections of this
Agreement are inserted for convenience of reference only and shall not be deemed to affect the
meaning or construction of any of the provisions hereof or thereof. Whenever the context and
construction so require, all words herein in the singular number herein shall be deemed to have
been used in the plural, and vice versa, and the masculine gender shall include the feminine and
neuter and the neuter shall include the masculine and feminine.

          (c) This Agreement may not be changed, amended, restated, waived, supplemented, discharged,
canceled, terminated or otherwise modified orally or by any course of dealing or in any manner
other than as provided in the Credit Agreement or the applicable Credit Document. This Agreement
shall be considered part of the Credit Agreement and shall be a Credit Document for all purposes
under the Credit Agreement and other Credit Documents.

          (d) This Agreement, the Credit Agreement, and the Credit Documents constitute the final,
entire agreement and understanding between the parties with respect to the subject matter hereof
and thereof and may not be contradicted by evidence of prior, contemporaneous or subsequent oral
agreements between the parties, and shall be binding upon and inure to the benefit of the
successors and assigns of the parties hereto and thereto. There are no unwritten oral agreements
between the parties with respect to the subject matter hereof and thereof. If any provision of
this Agreement is adjudicated to be invalid under applicable laws or regulations, such provision
shall be inapplicable to the extent of such invalidity without affecting the validity or
enforceability of the remainder of this Agreement which shall be given effect so far as possible.

14

 

          (e) THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED
BY AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH THE CHOICE OF LAW PROVISIONS SET FORTH IN THE
CREDIT AGREEMENT AND SHALL BE SUBJECT TO THE WAIVER OF JURY TRIAL AND NOTICE PROVISIONS OF THE
CREDIT AGREEMENT.

          (f) No Credit Party may assign, delegate or transfer this Agreement or any of its rights or
obligations hereunder or thereunder and any delegation, transfer or assignment in violation hereof
shall be null and void. No rights are intended to be created under this Agreement for the benefit
of any third party donee, creditor or incidental beneficiary of any Credit Party or any other
Person other than Administrative Agent and each Lender. Nothing contained in this Agreement shall
be construed as a delegation to Administrative Agent of any Credit Party’s duties of performance,
including, without limitation, any duties under any account or contract in which Administrative
Agent has a security interest or Lien. This Agreement shall be binding upon the Credit Parties and
Lenders and their respective successors and permitted assigns. Administrative Agent’s and Lenders’
ability to assign, sell or transfer all of any part of this Agreement shall be governed by the
Credit Agreement.

          (g) Each Credit Party hereby (i) reaffirms its obligations under the Credit Agreement and each
of the other Credit Documents to which it is a party, and (ii) agrees that each of such Credit
Documents remain in full force and effect and are hereby ratified and confirmed. All
representations and warranties made in this Agreement shall survive the execution and delivery of
this Agreement and no investigation by Administrative Agent shall affect such representations or
warranties or the right of Administrative Agent to rely upon them.

          (h) Each Credit Party shall execute and deliver such other documents, certificates and/or
instruments and take such other actions as Administrative Agent or Requisite Lenders may reasonably
request in order more effectively to consummate the transactions contemplated hereby. In
furtherance and not in limitation of the foregoing, each Credit Party agrees that if so requested
by any Lender pursuant to Section 2.5 of the Credit Agreement (Evidence of Debt; Register;
Lenders’ Books and Records; Notes), Company shall execute and deliver to such Lender (and/or, if
applicable and if so specified in such request, to any Person who is an assignee of such Lender
pursuant to Section 10.6 of the Credit Agreement (Successors and Assigns; Participations))
an amended or amended and restated Note or Notes to evidence such Lender’s Term Loan and naming
Company as obligor thereunder.

[SIGNATURE PAGES FOLLOW]

15

 

[SIGNATURE PAGES TO RATIFICATION AND

AMENDMENT AGREEMENT (RELATING TO XO MERGER)]

     IN WITNESS WHEREOF, the parties have caused this Ratification and Amendment Agreement
(Relating to XO Merger) to be duly executed and delivered by their respective officers thereunto
duly authorized as of the date first written above.

	 	 	 	 	 	 	 
	 	 	Requisite Lenders:	 	 
	 
	 	 	 	 	 	 
	 	 	ARNOS CORP.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Edward E. Mattner	 	 
	 

	 	 	 	 

Name: Edward E. Mattner
	 	 
	 

	 	 	 	Title: Vice President	 	 
	 
	 	 	 	 	 	 
	 	 	Agreed and Acknowledged:	 	 
	 
	 	 	 	 	 	 
	 	 	Company:	 	 
	 
	 	 	 	 	 	 
	 	 	XO COMMUNICATIONS, LLC	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Carl J. Grivner	 	 
	 

	 	 	 	 

Name: Carl J. Grivner
	 	 
	 
	 	 	 	Title: President and Chief Executive
Officer

[SIGNATURES CONTINUE ON NEXT PAGE]

 

[SIGNATURE PAGES TO RATIFICATION AND

AMENDMENT AGREEMENT (RELATING TO XO MERGER) — CONTINUED]

	 	 	 	 	 	 	 
	 	 	Guarantors:
	 
	 	 	 	 	 	 
	 	 	XO HOLDINGS, INC.
	 	 	LMDS HOLDINGS, INC.
	 	 	COAST TO COAST TELECOMMUNICATIONS, INC.
	 	 	LHP EQUIPMENT, INC.
	 	 	TELECOMMUNICATIONS OF NEVADA, LLC
	 	 	V&K HOLDINGS, INC.
	 	 	XO ASIA LIMITED
	 	 	XO COMMUNICATIONS SERVICES, INC.
	 	 	XO DATA SERVICES, LLC
	 	 	XO GLOBAL COMMUNICATIONS, INC.
	 	 	XO INTERACTIVE, INC.
	 	 	XO INTERCITY HOLDINGS NO.1, LLC
	 	 	XO INTERCITY HOLDINGS NO.2, LLC
	 	 	XO INTERNATIONAL HOLDINGS, INC.
	 	 	XO INTERNATIONAL, INC.
	 	 	XO LONG DISTANCE SERVICES (VIRGINIA), LLC
	 	 	XO MANAGEMENT SERVICES, INC.
	 	 	XO MANAGEMENT SERVICES, NEVADA, INC.
	 	 	XO MINDSHARE, LLC
	 	 	XO NEVADA MERGER SUB, INC.
	 	 	XO SERVICES, INC.
	 	 	XO VIRGINIA, LLC
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ William Garrahan
	 	 	 	 	 
	 	 	 	 	Name:	 	William Garrahan
	 

	 	 	 	Title:	 	Acting Chief Financial
Officer and Senior Vice President

 

[SIGNATURE PAGES TO RATIFICATION AND

AMENDMENT AGREEMENT (RELATING TO XO MERGER) — CONTINUED]

	 	 	 	 	 	 	 
	 	 	Administrative Agent:	 	 
	 
	 	 	 	 	 	 
	ACKNOWLEDGED AND AGREED SOLELY	 	MIZUHO CORPORATE BANK, LTD
	FOR PURPOSES OF SECTION 6(b):
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Shiro Shiraishi	 	 
	 

	 	 	 	 

Name: Shiro Shiraishi
	 	 
	 

	 	 	 	Title: Vice Presidentexv10w33

 

Exhibit 10.33

THE
REGISTRANT HAS APPLIED FOR CONFIDENTIAL TREATMENT OF CERTAIN
PROVISIONS OF
 THIS EXHIBIT WITH
THE SECURITIES AND EXCHANGE COMMISSION. THE CONFIDENTIAL PORTIONS
OF
 THIS EXHIBIT ARE MARKED WITH
ASTERISKS (*****) AND HAVE BEEN OMITTED. THE OMITTED PORTIONS
OF
 THIS EXHIBIT WILL BE FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
 A REQUEST FOR CONFIDENTIAL
TREATMENT.

LICENSE AGREEMENT

     This agreement (“Agreement”) entered into this 18th day of October, 2005 by and between
NOVAVAX, INC., a Delaware corporation having an address at 508 Lapp Road Malvern, Pennsylvania
19355 (hereinafter referred to as “NOVAVAX” or “Party”) and ESPRIT Pharma, Inc, having an address
at 2 Tower Center Boulevard, East Brunswick, NJ 08816, (hereinafter referred to as “ESPRIT” or
“Party”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed
in Article 1.

W I T N E S S E T H

     WHEREAS, NOVAVAX currently markets an estradiol-containing drug product called ESTRASORB and
is the owner of a New Drug Application relating to ESTRASORB as well as U.S. Patent No. 5,629,021,
Canadian Patent No. 2,211,262, and other patents and patent applications relating to micellar
nanoparticle technology.

     WHEREAS, ESPRIT wishes to acquire an exclusive license under such patents and patent
applications from NOVAVAX, and NOVAVAX is willing to grant such license to ESPRIT under the terms
and conditions of this Agreement.

     WHEREAS, concurrently with the execution and delivery of this Agreement, the parties have
entered into the Supply Agreement relating to the manufacture of Licensed Product and the provision
of related services and technology by NOVAVAX to ESPRIT.

     WHEREAS, concurrently with the execution and delivery of this Agreement and the Supply
Agreement, ESPRIT has executed and delivered to NOVAVAX the Promissory Note relating to $8.0
million of the consideration for this Agreement.

     WHEREAS, concurrently with the execution and delivery of this Agreement, the Supply Agreement
and the Promissory Note, *****.

     WHEREAS, the parties intend that this Agreement, other than Sections 3(a), 3(b), and 3(c)
hereof which will be effective on the date of this Agreement, will not be effective until the
Business Day immediately following the satisfaction in full of ESPRIT’s obligations to pay
principal and interest under the Promissory Note on the Maturity Date (as defined therein).

     NOW, THEREFORE, in consideration of the above premises and the covenants contained herein, the
parties agree as follows:

 

			
	*	 	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.

 

 

ARTICLE 1 — DEFINITIONS

     As used in this Agreement, the following terms, when used with initial capital letters, shall
have the following meanings, the singular shall include the plural and vice-versa:

          “Affiliate” means any entity that directly or indirectly controls, is controlled by, or is
under common control with a Party, and for such purpose “control” shall mean (i) directly or
indirectly owning, controlling or holding more than fifty percent (50%) of the securities or other
ownership interests representing the equity, the voting stock or general partnership interest in an
entity or (ii) the possession, direct or indirect, of the power to direct or cause the direction of
the management or the policies of the entity, whether through the ownership of voting securities,
by contract or otherwise. Any such corporation, entity or business structure shall only be
considered an Affiliate for so long as such ownership or control exists.

          “Business Day” means any day other than Saturday, Sunday, holiday or any other
day on which banks in New York, New York are permitted or required to be closed. Unless otherwise
specified herein, “day” will mean calendar day.

          “Calendar Quarter” means each of the periods of time between January and March, April and
June, July and September, and October and December.

          “Calendar Year” means the period of time commencing on 1 January and ending on the following
December 31.

          “Commercial Sale” and words of similar import means, an arm’s length transaction and shipment
by ESPRIT, its Affiliates or each of its sublicensees of a Licensed Product to an independent third
party in a country of the Territory.

          “Commitment to Fund” means the agreement by each of the Private Equity Investors to fund
ESPRIT with the principal amount due under the Promissory Note within ten (10) Business Days of
such default for the express purpose of satisfying ESPRIT’s obligations under the Promissory Note.

          “Confidential Information” has the meaning set forth in Section 6.1.

          “Dollar” means the legal currency of the U.S.

          “Effective Date” means, (a) with respect to ESPRIT’s obligations under Section 3.1(a), 3.1(b),
and 3.1(c), the date of this Agreement and (b) with respect to all other terms and conditions of
this Agreement, the Business Day immediately following the satisfaction in full of ESPRIT’s
obligations to pay principal and interest under the Promissory Note on the Maturity Date (as
defined therein).

          “ESPRIT Improvement” means any and all Improvements created, conceived or first reduced to
practice by ESPRIT, or its Affiliates, agents, subcontractors or sublicensees, alone or with others
(excluding NOVAVAX).

          “ESPRIT Improvement Intellectual Property” means Intellectual Property included in ESPRIT
Improvements.

2

 

          “ESPRIT Improvement Patents” means patents and patent applications that describe and claim
ESPRIT Improvements.

          “ESPRIT Sole Technology” means Intellectual Property that is first conceived and first reduced
to practice during the term of this Agreement solely by personnel employed by or on behalf of
ESPRIT.

          “FDA” means the United States Food and Drug Administration and successor bodies or
corresponding foreign administrative bodies.

          “Field” means the use, manufacture or sale of topically- or transdermally-administered
products containing no active ingredient other than17ß estradiol (excluding contraceptive products,
Selective Estrogen Receptor Modulators and products administered vaginally, orally, nasally,
through the gum or by injection) which utilize NOVAVAX’s micellar nanoparticle technology in the
field of women’s health in products that are marketed under NOVAVAX’s NDA #21-371.

          “First Commercial Sale” means, with respect to any Licensed Product, the first Commercial
Sale.

          “Fiscal Year” means the period of time commencing on the Monday following the Sunday closest
to the end of the calendar month of December and terminating on the Sunday closest to the end of
the immediately succeeding December.

          “GAAP” means U.S. generally accepted accounting principles, consistently applied.

          “Improvement” means any change, improvement, development, or modification of a Licensed
Product with respect to formulation technology, any component/material utilized in the formulation
technology, or the method or process of making or using a Licensed Product utilizing the
formulation technology, that (a) is made, conceived of or reduced to practice by either Party or
their Affiliates, agents, subcontractors or sublicensees, alone or with others, or as a result of
work performed on a Licensed Product during the term of this Agreement and (b) is covered by or
derived or resulting from the practice of Licensed Patents, patents, patent applications and other
Intellectual Property rights in or that cover any of the foregoing.

          “Improvement Patent” means patents and patent applications that describe and claim
Improvements.

          “IND” has the meaning set forth in Section 10.3(c).

          “Intellectual Property” has the meaning set forth in Section 5.1.

          “Joint Improvement” means any and all Improvements created, conceived or first reduced to
practice during the term of this Agreement by NOVAVAX, or its Affiliates, agents, subcontractors or
sublicensees, and ESPRIT, or its Affiliates, agents, subcontractors or sublicensees. Joint
Improvement shall not include any Improvement that is a NOVAVAX Improvement or an ESPRIT
Improvement.

3

 

          “Joint Improvement Intellectual Property” means Intellectual Property included in Joint
Improvements.

          “Joint Improvement Patents” means patents and patent applications that describe and claim
Joint Improvements.

          “Launch” means the date of the First Commercial Sale of any Licensed Product.

          “Licensed Know-How” means, to the extent relating and necessary to the manufacture of a
Licensed Product, all information or special knowledge on the part of NOVAVAX as of the Effective
Date not generally known to the public, including but not limited to inventions, discoveries,
reports, protocols, processes, apparati, techniques, methods, models, screens, assays, products,
regulatory submissions, and technical information, together with all experience, data, formulas,
procedures and results, and including all chemical, pharmacological, toxicological, clinical,
analytical, quality control, and safety data (including but not limited to data from use of the
Licensed Product), and any other materials or compositions relating to the manufacture of a
Licensed Product or being useful in the manufacture, use, sale or Registration of a Licensed
Product as reasonably determined by NOVAVAX; except to the extent that the disclosure of such
information or special ability is prohibited by law, rule, regulation, order, treaty, contract,
agreement or other obligation.
Licensed Know-How also includes the NOVAVAX Improvement Intellectual Property as set forth in
section 5.2.4 hereof to the extent not disclosed in any patent or patent application of the
Licensed Patents. Licensed Know-How shall constitute Confidential Information of NOVAVAX in
accordance with Section 6.

          “Licensed Patent” means U.S. Patent No. 5,629,021, Canadian Patent No. 2,211,262, including
any other of their respective counterparts in the Territory, as well as all continuations,
continuations-in-part, divisions, renewals, reissues, reexaminations, extensions, and patents of
addition and patents of importation of the foregoing containing a Valid Claim that would be
infringed by the use or sale of a Licensed Product by ESPRIT, its affiliates or its permitted
sublicensees, in the Territory but for the licenses granted herein. In addition, Licensed Patents
shall include NOVAVAX Improvement Patents, NOVAVAX’s interests in Joint Improvement Patents and any
other patents owned by NOVAVAX that are necessary for ESPRIT to practice the patents described in
the preceding sentence.

          “Licensed Product” means any topically- or transdermally-administered product containing no
other active ingredient other than 17ß estradiol which is marketed under NOVAVAX’s NDA #21-371, the
use, sale or manufacture of which would, but for a license, infringe a Valid Claim of a Licensed
Patent or an Improvement Patent in the country in which it is sold. Licensed Products include
Improvements made by NOVAVAX related to formulation and for Licensed Product packaging.

          “Licensed Technology” means Licensed Patents and Licensed Know-how.

          “NDA” has the meaning set forth in Section 10.3(c).

4

 

          “Net Sales” means, on a country-by-country basis (a) for any bona fide arm’s length
transaction in which Licensed Products are Commercially Sold separately by ESPRIT, its Affiliates,
and its permitted sub-licensees to independent third parties (rather than bundled with any other
products or services), the amount invoiced for the sale of Licensed Products in finished packaged
form, and (b) for all other transactions in which Licensed Products are sold, used or otherwise
disposed of by ESPRIT, its Affiliates and its permitted sublicensees (including in barter or
similar transactions, or transactions that are not at arm’s length to a third
party, or transactions in which Licensed Products are not sold separately), the total sales price
for Products in such transactions; less, in the case of clause (a) and (b) above (i) all normal and
customary trade and quantity discounts, (ii) allowances, chargebacks, wholesaler fees and
deductions, retailer fees and deductions, rebates, including government and managed care rebates,
and credits determined in accordance with GAAP, and returns and replacements determined in
accordance with GAAP, less any freight charges paid by third parties for delivery and less excise,
value added and other taxes and or/duties applicable to sales of Licensed Products which the
selling party has to pay or absorb on such sales. Further, Net Sales shall not include normal and
customary promotional samples, including, subject to the foregoing, any samples affixed to or
accompanying other products of ESPRIT or any of its Affiliates, coupons or other promotional
incentives.

          “NOVAVAX Improvement” means any and all Improvements created, conceived or first reduced to
practice by NOVAVAX, or its Affiliates, agents, subcontractors or sublicensees, alone or with
others (excluding ESPRIT).

          “NOVAVAX Improvement Intellectual Property” means Intellectual Property included in NOVAVAX
Improvements.

          “NOVAVAX Improvement Patents” means patents and patent applications that describe and claim
NOVAVAX Improvements.

          “Promissory Note” means that certain $8.0 million promissory note due December 30, 2005 issued
and delivered on the date hereof by ESPRIT to NOVAVAX.

          “Registration” means a filing with a governmental authority for the purpose of obtaining legal
and regulatory approval to conduct clinical trials for a product or to commence making, using,
and/or selling a product, including an NDA filing or its equivalent in the Territory.

          “Supply Agreement” means a separate agreement to be executed and delivered concurrently with
this Agreement under which NOVAVAX shall supply Licensed Product to ESPRIT.

          “Territory” means the United States (including Puerto Rico), Mexico and Canada.

          “Trademarks” means all registered and unregistered trademarks listed on Schedule 1
attached hereto.

          “Valid Claim” means a claim or pending claim in any unexpired, enforceable, issued patent
within the Licensed Patent or Improvement Patent which has not been held invalid by a non-appealed
or unappealable decision by a court or other appropriate body of competent jurisdiction, and which
is not admitted to be invalid through disclaimer or dedication to the public.

5

 

          “Year” shall mean the period of time commencing on the calendar day of the First Commercial
Sale of a Licensed Product and ending three hundred and sixty four (364) days thereafter.

ARTICLE 2 — GRANT OF RIGHTS 

     2.1 Subject to the terms and conditions hereof, NOVAVAX hereby grants to ESPRIT, commencing on
the Effective Date, an exclusive license under the Licensed Patents and Licensed Know-how to make
and have made, import, use, sell, offer for sale, and have sold Licensed Product (including under
the Trademark) in the Territory in the Field.

     2.2 Subject to the terms and conditions hereof, NOVAVAX hereby grants to ESPRIT, commencing on
the Effective Date, an exclusive license to the NOVAVAX Improvement Intellectual Property to make
and have made, import, sell, offer to sell, and have sold Licensed Product in the Territory in the
Field.

     2.3 ESPRIT shall have the right to sublicense commencing on the Effective Date the rights
granted under Sections 2.1 and Section 2.2 of this Agreement on terms substantially similar to
those contained herein to a controlled Affiliate of ESPRIT and to non-Affiliated third
parties, provided that any such sublicense to non-Affiliated third parties would require the
prior written approval of NOVAVAX which will not be unreasonably withheld or delayed; and provided,
further that ESPRIT shall require its permitted sublicensees to comply with all of the obligations
of ESPRIT contained in this Agreement and ESPRIT shall be responsible for the performance by such
sublicensees of such obligations.

     2.4 ESPRIT hereby grants to NOVAVAX an exclusive, perpetual, worldwide paid up royalty-free
license, with rights to sublicense, under ESPRIT Improvement Intellectual Property and ESPRIT’s
interests in Joint Improvement Intellectual Property for use outside the Field.

     2.5. Except as otherwise expressly provided in this Agreement, under no circumstances shall a
Party hereto, as a result of this Agreement, obtain any ownership interest or license in or other
right to any technology, know-how, patents, patent applications, products, or biological materials
of the other Party, including, but not limited to, items owned, controlled or developed by the
other Party, at any time pursuant to this Agreement. This Agreement does not create, and shall
under no circumstances be construed or interpreted as creating, an obligation on the part of either
Party to grant any license to the other Party other than as expressly set forth herein. Any
further contract or license agreement between the Parties shall be in writing.

     2.6 All rights and interests not expressly granted to ESPRIT are reserved by NOVAVAX (the
“Reserved Interests”) for itself, its Affiliates and partners (other than ESPRIT) and other
licensees and sublicensees, including, but not limited to, the rights to use and grant licenses
under the Licensed Technology or any other technology owned or controlled by NOVAVAX to make, have
made, use, offer to sell, sell, have sold and import products

6

 

(other than a license under Licensed
Technology for Licensed Products in the Field, for so long as ESPRIT has an exclusive license under
Licensed Technology for Licensed Products in the Field). It shall not be a breach of this
Agreement for NOVAVAX, acting directly or indirectly, to exploit its Reserved Interests in any
manner anywhere in the Territory, provided, however, that under no circumstances shall NOVAVAX
utilize its Reserved Interests to make, have made, use, offer to sell, sell, have sold or import
Licensed Products or related Improvements in the Territory in the Field.

ARTICLE 3 — PAYMENTS

     3.1 In consideration of the license granted hereunder, ESPRIT shall make the following
payments in Dollars to NOVAVAX as follows:

     (a) Upon the Business Day immediately following the date of this Agreement, ESPRIT shall pay
NOVAVAX an amount equal to Two Million Dollars ($2,000,000) in cash by wire transfer.

     (b) Upon the Business Day immediately following the date of this Agreement, ESPRIT shall pay
NOVAVAX an amount equal to Eight Million Dollars ($8,000,000) in the form of the Promissory Note.

     (c) Upon the first anniversary of the date of this Agreement, ESPRIT shall pay NOVAVAX an
amount equal to Two Million Five Hundred Thousand Dollars ($2,500,000) in cash by wire transfer.

     (d) ESPRIT will, or will cause its designated Affiliates to, pay NOVAVAX the following
one-time sales milestone payments (each a “Milestone Payment”) within *****
( ***** ) days after the first satisfaction of the following sales milestones (each a
“Milestone”):

	 	 	 	 	 
	 	 	Milestone	 
	Milestone	 	Payment	 
	1. Upon reaching an annual Net Sales level of ***** Dollars
($*****), a one-time payment during the period in which this
	 	***** Dollars
	sales level is first reached
	 	 	($*****	)
	2. Upon reaching an annual Net Sales level of ***** Dollars
($*****), a one-time payment during the period in which this
	 	***** Dollars
	sales level is first reached
	 	 	($*****	)
	3. Upon reaching an annual Net Sales level of ***** Dollars
($*****), a one-time payment payable during the period in
	 	***** Dollars
	which this sales level is first reached
	 	 	($*****	)
	4. Upon reaching an annual Net Sales level of ***** Dollars
($*****), a one-time payment payable during the period in
	 	***** Dollars
	which this sales level is first reached
	 	 	($*****	)
	5. Upon reaching an annual Net Sales level of ***** Dollars
($*****), a one-time payment payable during the period in
	 	***** Dollars
	which this sales level is first reached
	 	 	($*****	)

 

			
	*	 	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.

7

 

The Net Sales levels shall not be cumulative from annual Net Sales period to annual Net Sales
period. The parties understand that more than one payment may be made during any single annual Net
Sales period. The annual Net Sales shall be calculated in the following two ways: (1) on December
31st of each Calendar Year (commencing with the first Calendar Year following Launch)
for the previous twelve (12) months; and (2) on July 1 of each Calendar Year (commencing with the
first Calendar Year following Launch) for the previous twelve (12) months. If, according to at
least one of the foregoing calculations, the annual Net Sales level reaches a Milestone as
specified in the above table, ESPRIT or its Affiliates shall pay NOVAVAX a specified Milestone
Payment during the period in which the Milestone is first reached. For example, if the Net Sales
in calendar year 2006 is $ *****, then no Milestone Payment would be made. If by July 1,
2007, the Net Sales for the twelve months prior to July 1, 2007 equals or exceeds $ *****,
ESPRIT or its Affiliates would pay NOVAVAX a $ ***** in Payments with respect to such
Period.

ARTICLE 4 — ROYALTIES

     4.1 ESPRIT will, or will cause its designated Affiliates to, pay NOVAVAX quarterly royalties
on the sales of Licensed Products in the Territory in an amount equal to ***** percent (*****%) of
the Net Sales in any Calendar Quarter commencing in the first Calendar Year following Launch.

     4.2 No royalties due under this Article shall be payable on sales transactions as among
ESPRIT, any of its Affiliates and sublicensees. The final vendee sale to a third party alone shall
be used for the purposes of determining the royalty payments due hereunder. Only one royalty
payment shall be payable on the sale of each Licensed Product, and the amount of such royalty will
be provided in accordance with this Article 4 and the sales date of the Licensed Product to an
independent third party. Licensed Products shall be sold only for cash consideration and there
shall be no discounting of price to the disadvantage of the price of
Licensed Products that are included in or made part of any bundling of Licensed Products with
any existing or future ESPRIT or Affiliate product(s) as part of a sale to independent third
parties.

     4.3 ESPRIT shall not be obligated to pay any royalty payments based upon sales of a given
Licensed Product in a country of the Territory after the expiration of the last to expire Licensed
Patent or Improvement Patent having at least one (1) Valid Claim that would be infringed by the
sale of that Licensed Product by ESPRIT, its Affiliates or its sublicensees in that country but for
the licenses granted herein.

     4.4 All royalties shall be calculated and payable on a Calendar Quarter basis as of the end of
the each Calendar Quarter, and royalties shall be paid within ***** (*****)
days following the end of such Calendar Quarter. All royalties shall be calculated on a Licensed
Product by Licensed Product basis. Each royalty payment and Milestone Payment shall be accompanied
by a written report indicating the amount of Net Sales during such Calendar quarter or applicable
period together with a calculation of the royalties and Sales Milestone Payments due. ESPRIT shall
deliver the written report for each such Calendar Quarter or applicable period, regardless of
whether when any royalty payments or Milestone Payments are required to be paid in that Calendar
Quarter or applicable period, commencing in the first Calendar Year following Launch.

 

			
	*	 	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.

8

 

     4.5 NOVAVAX shall have the right, at its own expense, for the period during which a royalty or
Milestone Payment is due to NOVAVAX, to have a firm of independent certified public accountants, to
whom ESPRIT has no reasonable objection and subject to customary confidentiality restrictions,
solely to examine the relevant books and records of account of ESPRIT relating to the Licensed
Product during reasonable business hours and no more than ***** during each Fiscal Year, to
determine whether appropriate payment (including, without limitation, payment pursuant to Sections
3.1(c), 4.1 and 5.1) has been made by ESPRIT hereunder. The accountant shall disclose to NOVAVAX
only information relating to the accuracy of the royalty and Sales Milestone Payment reports and
the royalty payments and Milestone Payments made according to this Agreement. The information
received by the accountant, except for information necessary for disclosure to NOVAVAX to establish
the accuracy of such reports, shall be held confidential. If such accounting firm correctly
concludes that additional royalties or Milestone Payments were owed during such period, ESPRIT
shall pay the additional royalties within thirty (30) days of the date NOVAVAX delivers to ESPRIT
such accounting firm’s written report so correctly concluding. If the amount of such additional
royalties or Milestone Payments owed exceeds ***** percent (*****%) of the amount of royalty
payments or Sales Milestone Payments actually made by ESPRIT for such period, ESPRIT shall
reimburse NOVAVAX for the commercially reasonable fees and expenses of the accounting firm incurred
in the conduct of the applicable audit.

     4.6 The remittance of Milestone Payments or royalties payable on sales outside the U.S. will
be payable to NOVAVAX in Dollars according to the official rate of exchange of the currency of the
country from which the royalties are payable as quoted by The Wall Street Journal, New York
edition, for the last day of the Fiscal Quarter or other applicable period for which the royalty
payment is made. If the transfer or the conversion into U.S. Dollars in any such instance is not
lawful or possible, the payment of such part of the Milestone Payment of royalties as is necessary
shall be made by the deposit thereof, in whatever currency is allowable and acceptable by NOVAVAX,
to the credit and account of NOVAVAX or its nominees in any commercial bank or trust company of its
choice located in that country. ESPRIT shall give prompt notice of such deposit to NOVAVAX.

     4.7 All royalties, Milestone Payments and other payments required hereunder shall be paid in
accordance with the instructions provided by NOVAVAX in immediately available funds by wire
transfer to a bank or other institution designated in writing by NOVAVAX from time to time.

ARTICLE 5 — LICENSED PRODUCT MANUFACTURE; INTELLECTUAL PROPERTY; REGULATORY MATTERS

     5.1 Intellectual Property. Any intellectual property rights, including without
limitation, patents, patent applications, inventions, and know-how (hereinafter referred to as
“Intellectual Property”) owned or controlled by either Party prior to the parties entering into
this Agreement shall remain the property of such Party, subject only to the rights and licenses
granted herein.

 

			
	*	 	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.

9

 

5.1.1 Any Intellectual Property that is first conceived and first reduced to practice during
the term of this Agreement solely by personnel employed by or on behalf of NOVAVAX shall
remain the property of NOVAVAX, subject to the rights and licenses granted herein.

5.1.2 Any Intellectual Property that is first conceived and first reduced to practice during
the term of this Agreement solely by personnel employed by or on behalf of ESPRIT shall
remain the property of ESPRIT, subject to the rights and licenses granted herein (“ESPRIT
Sole Technology”).

5.1.3 Any Intellectual Property that is first conceived or first reduced to practice during
the term of this Agreement by personnel employed by or on behalf of ESPRIT and personnel
employed by or on behalf of NOVAVAX (other than the Intellectual Property described in
Section 5.1.1 and Section 5.1.2) shall be and shall remain the joint property of NOVAVAX and
ESPRIT, subject to the rights and licenses granted herein (“Joint Intellectual Property”).
The parties agree to keep the Joint Intellectual Property in confidence on a basis consistent
with Article 6 and not to publicly disclose the same except in accordance with Article 6.

5.1.4 NOVAVAX Improvement Intellectual Property shall constitute Licensed Technology
throughout the term of this Agreement to the extent that such Intellectual Property is
relevant to the use, sale or Registration of a Licensed Product and to the extent that the
licensing of such Intellectual Property by NOVAVAX to ESPRIT pursuant to the terms of this
Agreement would not be prohibited by law, rule, regulation, order, treaty, contract,
agreement, or other obligation.

     5.2 Transfer of NDA and IND. The Parties agree and acknowledge that within 20 days
after the Effective Date and receipt of ESPRIT’s written request, NOVAVAX shall provide ESPRIT with
a letter addressed to the FDA authorizing and requesting that each NDA and IND owned by NOVAVAX and
pertaining to the Licensed Product in the Territory, as the case maybe, be transferred, in its
entirety, to the name of ESPRIT. NOVAVAX shall provide ESPRIT with a copy of the letter and ESPRIT
shall promptly send a letter to the FDA accepting the NDA and IND. NOVAVAX will be entitled to
copy and reference the NDA and IND, and
any safety database or other safety information related to the Licensed Product, outside the
Territory freely as it determines. Each party will notify the other immediately by telephone (with
prompt written follow-up) of any inquiry, contact or communication received from any governmental
regulatory agency or other official body (within or outside of the Territory) which relates to the
Licensed Product or any component or ingredient thereof, and will promptly furnish the other party
with copies of all written communications relating thereto sent to or received from such regulatory
agency. ESPRIT shall consult with NOVAVAX prior to making a material modification to the NDA or
IND pertaining to the Licensed Product, and shall consider in good faith NOVAVAX’s views with
respect to the impact any such modification may have on the marketing and commercialization of the
Licensed Product outside of the Territory. ESPRIT shall provide, at NOVAVAX’s expense, such
cooperation as may be reasonably to assist NOVAVAX in referencing the NDA or IND pertaining to
Licensed Product or safety information related to Licensed Product in connection with regulatory
applications and approvals for Licensed Product outside of the Territory made by NOVAVAX or
NOVAVAX’s licensees; provided that, in ESPRIT’s reasonable judgment, such assistance is not unduly
burdensome to ESPRIT’s senior management. NOVAVAX hereby retains and

10

 

ESPRIT hereby grants to
NOVAVAX the perpetual exclusive, fully paid up right to use with the right to sublicense ((i)
outside the Field and (ii) in the Field but outside the Territory) all data created by under or in
connection with the NDA and the IND.

     5.3 Maintenance of NDA. ESPRIT shall bear responsibility for, and shall bear all
costs related thereto, to take such actions as may be necessary, in accordance with accepted
business practices and legal requirements, to obtain and maintain the authorization and/or ability
to market the Licensed Product in the Territory. Without limiting the generality of effect of the
foregoing, ESPRIT shall be responsible for all of the PDUFA fees, including, without limitation,
establishment fees and product fees, associated with NDA. The establishment fees will be allocated
on a pro rata basis agreed upon by the parties in the event other FDA approved product(s) are
manufactured by Novavax at the Cardinal facility.

     5.4 Communications with Regulatory Authorities. ESPRIT shall have the responsibility,
and shall bear all costs related to, communications with any government agencies to satisfy its
requirements regarding the authorization and/or continued authorization to market the Licensed
Product in commercial quantities in the Territory. NOVAVAX shall
promptly notify ESPRIT of any inquiry or other communication that it receives from the FDA
concerning the Licensed Product. ESPRIT shall handle all communications with the FDA concerning
the Licensed Product (other than with respect to the manufacture thereof which will be handled by
NOVAVAX), including but not limited to reporting adverse reactions and responding to any inquiries
concerning advertising or promotional materials, and shall provide copies of all such communication
to NOVAVAX. NOVAVAX, however, shall be able to communicate with such governmental agency regarding
the Licensed Product if:

          (a) Such communication is necessary to comply with the terms of this Agreement or the
requirements of any law, governmental order or regulation; or

          (b) NOVAVAX, if practical, made a request of such agency to communicate with ESPRIT instead,
and such agency refused such request;

          (c) Such communication relates to the CMC Section of the NDA for the Licensed Product,
manufacturing specifications related to the Licensed Product;

          (d) provided, however, that before making any communication under (a), (b) or (c) of this
Section, NOVAVAX shall give ESPRIT notice as soon as possible of NOVAVAX’s intention to make such
communication, and ESPRIT shall be permitted to accompany NOVAVAX, take part in any such
communications and receive copies of all such communications.

     5.5 Medical Inquiries. ESPRIT shall respond to medical questions or inquiries
relating to the Licensed Product and shall instruct its sales force to direct medical inquiries
either to its own medical personnel or to the ESPRIT toll-free number referred to in Section 5.6,
within a reasonable time from the Effective Date. ESPRIT shall designate an individual to serve as
medical liaison in order to ensure consistency in the handling of medical inquiries. The medical
liaison will regularly review Licensed Product inquiries and responses and will also be available
for responding to non-routine inquiries should these arise.

     5.6 Toll-Free Number. ESPRIT shall maintain a toll-free telephone number to provide
information in response to inquiries from health care professionals and consumers. This number
shall be noted in all appropriate advertising and promotional materials, except that NOVAVAX may,
at its own option, use a different number in advertising and promotional materials that it develops
for use outside of the Territory.

11

 

     5.7 Adverse Reactions; Recalls. Except as otherwise set forth in the Supply
Agreement, ESPRIT shall be responsible for handling all complaints from customers in the Territory
relating to adverse reaction reports, adverse events, and recall activities with respect to the
Licensed Product. NOVAVAX shall promptly transfer and notify ESPRIT of any such complaints, and
shall cooperate with ESPRIT as necessary to resolve or address the situation, including, without
limitation, by providing detailed distribution records to ESPRIT.

     5.8 NDC Number. The Parties acknowledge and agree that (a) the Licensed Product may
be distributed initially for up to 90 days under the National Drug Code number for the Licensed
Product assigned to NOVAVAX and (b) ESPRIT shall be responsible, at its expense, for complying with
on NOVAVAX’s behalf, or assisting NOVAVAX in its compliance, with all FDA and other obligations or
requirements (including without limitation adverse reaction reports, adverse events, and recall
activities) applicable to NOVAVAX as a result of any and all distribution of the Licensed Product
under the National Drug Code number for the Licensed Product assigned to NOVAVAX.

     5.9 Withdrawal of NDA. ESPRIT will not take any action or omit to take any action
that could reasonably be expected to result in withdrawal of the NDA.

     5.10 Recall. In the event that either Party determines that an event, incident
or circumstance has occurred which may result in the need for a recall or other removal of any
Licensed Product, or any lot or lots thereof, from the market, it shall promptly advise and consult
with the other Party with respect thereto. The parties shall jointly make the final determination
to recall or otherwise remove a Licensed Product or any lot or lots thereof from the market. ESPRIT
shall be responsible for the costs of any recall except if such recall is solely the result of any
failure of NOVAVAX to manufacture Licensed Product in accordance with written specifications agreed
upon by the parties under the Supply Agreement.

     5.11 Commercially Reasonable Efforts. ESPRIT agrees that it will and will cause
its sublicensees and Affiliates to use commercially reasonable efforts to market and sell the
Licensed Product.

     5.12 LED Studies. The costs and expenses of any lowest effective dose study
relevant to Licensed Product (an “LED Study”) will be borne as follows: (a) the first $***** by
ESPRIT and (b) any amount in excess of $***** by ESPRIT subject to reimbursement by NOVAVAX of
*****% of such excess (such reimbursement not to exceed $***** in any single Calendar Year) if and
only to the extent that Milestone Payments have been made in accordance with this Agreement.
Without limiting the generality or effect of the foregoing, NOVAVAX will be entitled to review and
approve protocols relating to any LED Study.

ARTICLE 6 — CONFIDENTIALITY AND PUBLICITY

     6.1 All information disclosed by one Party to the other(s) or developed by the parties
pursuant to the terms of this Agreement (the “Confidential Information”) shall be maintained
strictly confidential and used only for the purposes of this Agreement in accordance with this
Article 6 (“Purposes”). Each Party may also disclose the other’s information to an Affiliate,

 

			
	*	 	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.

12

 

agent or consultant, who is under a written obligation of confidentiality and non-use at least
substantially equivalent to the obligations of this Article 6, with the exceptions that (i) ESPRIT
may disclose such information to its Affiliates who agree to maintain such information in
confidence and to use such information only for the Purposes and (ii) the Parties shall each be
free to disclose the existence of this Agreement and the nature of the licenses granted hereunder
to its Affiliates and other prospective licensees and sub-licensees, investors or prospective
investors, lenders and other potential funding sources, or to a third party in connection with a
merger or acquisition or proposed merger or acquisition, subject to an obligation of
confidentiality and non-use, provided that such Party shall have used commercially reasonable
efforts to obtain a written confidentiality agreement from such third party contemplated by this
sentence. Each Party shall guard any confidential information of the other Party with the same
level of diligence as it normally guards any of its own internal confidential, proprietary
information. Each Party shall be responsible for the breach of any of the provisions of this
Article 6 by a person or entity to whom such Party discloses information contemplated hereby.
Notwithstanding the foregoing, each Party shall be relieved of the confidentiality and limited use
obligations of this Agreement if:

          (a) the information was previously known to the receiving Party as evidenced by the prior
written records of such Party without disclosure by the disclosing Party;

          (b) the information is or becomes generally available to the public through no fault of the
receiving Party;

          (c) the information is acquired in good faith in the future by the receiving Party from a
third party not under an obligation of confidence to the disclosing Party with respect to such
information; or

          (d) the information is independently developed by the receiving Party without reliance on,
reference to, or knowledge of, the information disclosed by the disclosing Party.

The parties understand and agree that it shall be the receiving Party’s burden of proof to show the
applicability of any of the exceptions set forth in clauses (a), (b) (c) or (d) above.

     6.2 Notwithstanding the above obligations of confidentiality and non-use a Party may:

          (a) disclose information to a regulatory agency that is necessary to obtain regulatory
approval in a particular jurisdiction; or

          (b) disclose information to a government agency if the disclosure is necessary to protect the
health and safety of the Party’s workers or the public or as required by law; or

          (c) disclose information as and to the extent required to comply with applicable laws and
regulations, including the rules and regulations of the U.S. Securities and Exchange Commission.

     In making such disclosures as set forth in this Section 6.2, the disclosing Party shall use
reasonable efforts to promptly first notify the owner of the confidential information so as to
allow the owner of the confidential information an opportunity to seek a protective order or
otherwise limit any such disclosure. In any event, the disclosing Party shall use reasonable
efforts to only disclose such information as is required to be disclosed pursuant to the law,
regulation, rule or order, and shall use its reasonable efforts to obligate the recipient to
secrecy on the same terms as set forth herein. Each Party shall restrict the disclosure of
confidential information of the other so that only the persons that need to know it shall be
informed and the disclosure be limited to only such portions as necessary for the purposes of this
Agreement.

13

 

     6.3 Each Party shall not state or imply, in any publication, advertisement, sales promotional
material, or other medium:

     a) the name of the other Party or the name(s) of any employee(s) of the other Party; or

     b) the name of any Affiliate of the other Party or the name(s) of any employee(s) of such
Affiliate

without the prior written consent of the other Party.

     6.4 Except for the filing of a copy of this Agreement with the Securities and Exchange
Commission or other securities commission of such other jurisdictions whose laws may apply to
either Party to the extent required by law and such other public announcements as may hereafter
become required by law, regulation or rule due to changes from the facts and circumstances in
existence as of the Effective Date, no Party hereunder shall disclose this Agreement or make any
public announcement or filing concerning this Agreement or the subject matter hereof without the
prior written consent of the other. In the event that pursuant to the foregoing a Party shall file
a copy of this Agreement with the Securities and Exchange Commission or other securities commission
of such other jurisdictions whose laws may apply to either Party, it shall use reasonable efforts
seek confidential treatment for all portions thereof reasonably requested by the other Party. Any
proposed announcement or filing by a Party shall be made available to the other Party in advance of
publication or filing, as the case may be, for review and comment. If a Party decides to make an
announcement or disclosure required by law or as otherwise permitted under this section of this
Agreement, it will provide the other Party with at least ten (10) Business Days, where possible,
advance written notice of the text of any such written announcement or disclosure or content of any
non-written disclosure or announcement, except to the extent applicable law requiring disclosure
would not permit such advance notice (such as in the case of certain securities filings), in which
case the disclosing Party will give the maximum notice possible under the circumstances, so that
the other Party will have an opportunity to comment upon the announcement or disclosure.

     6.5 Except for permissible publications under this Article 6, neither Party will publish any
information based upon or derived from the work performed under this Agreement without the prior
review and consent of the Parties pursuant to this Section 6.5.

     6.6 With respect to information disclosed on or after the Effective Date between ESPRIT and
NOVAVAX under the provisions of this Agreement, the provisions of this Agreement shall govern and
prevail. In the event of any conflict between this Agreement and
any other pending confidentiality agreement between ESPRIT and NOVAVAX, with respect to information
disclosed on or after the Effective Date, the terms of this Agreement shall govern and prevail.

ARTICLE 7 — PATENT PROSECUTION AND MAINTENANCE

     7.1 Subject to Section 7.4 of this Agreement, NOVAVAX shall have sole authority and agrees to
prosecute or cause to be prosecuted to allowance or final rejection the patent applications
(including any reissue patent applications or reexamination patent applications) included in the
Licensed Patents that are owned or controlled by NOVAVAX, in whole or in part, including the Joint
Improvement Intellectual Property (hereinafter collectively “Patent Applications”), in the
countries in which the Licensed Patents are being prosecuted or maintained as of the Effective
Date. NOVAVAX shall issue as a patent each such Patent Application prosecuted to allowance at
NOVAVAX’s sole expense. NOVAVAX shall pay all attorneys fees and other costs associated with the
preparation, filing, and prosecution of such Patent Applications in the Territory included in the
Licensed Patents.

14

 

     7.2 NOVAVAX agrees to promptly provide (if not already provided and on an ongoing basis, as
the case may be) ESPRIT with copies of:

     (a) All Patent Applications included in the Licensed Patents;

     (b) All prior art searches it has performed (or has had performed) related to such
Patent Applications; and

     (c) All correspondence to and from the U. S. Patent and Trademark Office and foreign patent
offices relating to such Patent Applications.

     7.3 ESPRIT shall have the right to consult with NOVAVAX from time to time and on a reasonable
basis regarding the content of the Patent Applications included in the Licensed Patents, as well as
the prior art searches and correspondence related thereto, and to comment thereon. NOVAVAX shall
consider all such comments offered by ESPRIT, it being agreed, however, that all final decisions
respecting conduct of the prosecution of said patent applications shall rest solely in the
discretion of NOVAVAX.

     7.4 NOVAVAX shall promptly notify ESPRIT in the event NOVAVAX decides at any time to abandon
or discontinue prosecution of any one or more of the Patent Applications included in the Licensed
Patents. Such notification will be given as early as possible which in no event will be less than
forty-five (45) days prior to the date on which such Patent Application(s) will become abandoned.
ESPRIT shall have the option, exercisable upon written notification to NOVAVAX, to assume full
responsibility for the prosecution of the affected Patent Application(s), in which event such
affected Patent Application(s) shall, at ESPRIT’s option, be promptly exclusively licensed
royalty-free to ESPRIT and its sublicensees to make and have made, import, sell, offer to sell, and
have sold Licensed Product in the Territory in the Field.

     7.5 NOVAVAX shall pay all official taxes, annuities and fees required to keep in force all
Patent Applications and patents, which are included in the Licensed Patents, and shall submit
evidence, upon written request, to ESPRIT that said government fees have been timely paid. In the
event NOVAVAX decides not to pay the maintenance fee due on any one or more of said patents or
Patent Applications, NOVAVAX will give ESPRIT written notice of such decision at least sixty (60)
days in advance of the payment date. ESPRIT shall thereupon have the option to pay the maintenance
fees due on the affected patents or Patent Applications, in which case the affected Patent(s) or
Patent Application(s) shall, at ESPRIT’s option, be promptly exclusively licensed on an exclusive,
royalty free, perpetual and fully paid up basis to ESPRIT to make and have made, import, sell,
offer to sell, and have sold Licensed Product in the Territory in the Field.

     7.6 Each Party shall promptly disclose to the other any Improvements made, conceived or
reduced to practice by the disclosing Party or its Affiliates, agents, subcontractors or
sublicensees.

ARTICLE 8 — COMPETING PRODUCTS AND INFRINGEMENT

     8.1.1 If, during the term of this Agreement, NOVAVAX or ESPRIT becomes aware of infringing
sales of product competitive with Licensed Products by a third party in a given

15

 

Calendar Quarter in
a country of the Territory that are greater than ***** percent (*****%) of ESPRIT’s Commercial
Sales of such Licensed Products, by Dollar or equivalent legal currency
of the given country in the Territory, of Licensed Products in the Field in the same country
of the Territory and in the same Calendar Quarter that constitute infringement by a third party of
any issued patent (except for a patent relating to ESPRIT Sole Technology) included in the Licensed
Patents, that Party shall promptly notify the other Party in writing to that effect. ESPRIT shall
have the right, but not the obligation, to bring suit against any infringer of a patent relating to
ESPRIT Sole Technology at its own cost and expense.

     8.1.2 NOVAVAX shall have the initial right, but not the obligation, to initiate or prosecute
an infringement or other appropriate suit or action against any third party infringer of a Licensed
Patent at its own expense. ESPRIT has the right to join such suit or action at its own expense.
If, (a) after the expiration of ninety (90) days from said notice, NOVAVAX has not obtained a
discontinuance of such infringement or brought suit against the third party infringer, and (b) the
infringing product is competitive with Licensed Products, ESPRIT shall have the right, but not the
obligation, to bring suit (at ESPRIT’s sole expense) against such third party infringer, provided
that if NOVAVAX is joined to the suit, NOVAVAX will pay for its own litigation expenses.

     8.1.3 If, prior to the expiration of ninety (90) days from given notice under Section 8.1.1,
NOVAVAX obtains a discontinuance of such infringement or brings suit against the third party
infringer, and ESPRIT does not join the suit, then NOVAVAX shall retain all damages or other monies
awarded or received in settlement of such suit. ESPRIT will cooperate with NOVAVAX in any such
suit and shall have the right to consult with NOVAVAX and be represented by its own counsel at its
own expense.

     8.1.4 If, prior to the expiration of ninety (90) days from given notice under Section 8.1.1,
NOVAVAX brings suit against the third party infringer, and ESPRIT exercises its right to join the
suit, then each Party shall have the right to be represented by independent counsel in such
litigation at its own expense and neither Party shall incur any liability to the other Party as a
consequence of such litigation or any unfavorable decision resulting therefrom, including any
decision holding the patent invalid or unenforceable. Furthermore, any amounts recovered as a
result of any infringement action taken by the Parties hereunder shall be split equally.

     8.1.5 If, after the expiration of said ninety (90) days from the date of given notice under
Section 8.1.1, NOVAVAX has not obtained a discontinuance of such infringement or brought suit
against the third party infringer, and ESPRIT decides to exercise its right, after such ninety (90)
notice period, to bring suit against such infringer and join NOVAVAX as a party plaintiff, then
NOVAVAX will reasonably cooperate with ESPRIT in any suit for infringement of a patent of the
Licensed Patents brought by ESPRIT against a third party, and shall have the right to consult with
ESPRIT and to participate in and be represented by independent counsel in such litigation at its
own expense. Neither Party shall incur any liability to the other as a consequence of such
litigation or any unfavorable decision resulting therefrom, including any decision holding the
patent invalid or unenforceable. Furthermore, any amounts recovered as a result of any
infringement action taken by the Parties hereunder shall be split equally.

     8.1.6 Neither NOVAVAX nor ESPRIT may agree to settle pursuant to Section 8.1.4 or Section
8.1.5 without the prior written consent of the other Party, which shall not be unreasonably
withheld or delayed.

 

			
	*	 	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.

16

 

     8.1.7 Notwithstanding anything to the contrary contained herein, royalties, Milestone Payments
and all other payments hereunder shall continue unabated in accordance with the terms and
conditions of this Agreements during the pendancy (including all appeals) of any action
contemplated by Section 8. 1. 1 through and including Section 8.1.7.

     8.2.1 In the event NOVAVAX or ESPRIT receive notice or otherwise become actually aware of any
facts that that ESPRIT’s making, using or selling of a Licensed Product in the Field infringes,
will infringe or is alleged by a third party to infringe a third party patent, the Party becoming
aware of same shall promptly notify the other. NOVAVAX and ESPRIT shall thereafter attempt to
agree upon a course of action, which may include: (a) modifying of a Licensed Product or its use
and manufacture so as to be non-infringing; or (b) obtaining a license or assignment from said
third party.

     8.2.2 ESPRIT and NOVAVAX shall have the right to negotiate with said third party for such
license or assignment to the third party patent. In the event that such negotiation results in a
consummated agreement, then ESPRIT shall pay any lump sum payment and/or royalties to be paid
thereunder provided NOVAVAX has had an opportunity to review and consent to such
license agreement, which shall not be unreasonably withheld or delayed. Any of such lump sum
payments or royalties to be paid by ESPRIT and its sublicensees under such ESPRIT negotiated
agreement shall be creditable against royalties then due NOVAVAX hereunder. In no event shall
ESPRIT be entitled to credit against any royalty payments owed to the extent that any infringement
claim by a third party is not based solely upon a Licensed Product described in the above-mentioned
NDA (#21-371) or where the infringement claim is not based solely on ESPRIT’s use of the Licensed
Technology.

     8.2.3. In the event that ESPRIT is charged with patent infringement by a third party as a
result of ESPRIT’s making, using, and/or selling a Licensed Product and it cannot settle or has not
settled such infringement pursuant to the terms above, ESPRIT shall have the right to defend
against such charge of infringement. NOVAVAX shall have the opportunity to fully participate in
such defense at its own expense. If as a result of a final unappealable judgment in the litigation
or settlement thereof with the third party as described in the immediately preceding two sentences,
ESPRIT is required to pay royalties or other monies to such third party (“Third Party Payment”),
ESPRIT may thereafter offset such Third Party Payment (including running royalties and any and all
lump sum payments) against any royalties due but not yet paid hereunder to NOVAVAX, unless such
infringement claim by a third party is not based solely upon a Licensed Product described in the
above-mentioned NDA or where the infringement claim is not based solely on ESPRIT’s use of the
Licensed Technology. Any damages or other monies awarded or received in settlement of such
litigation against such adverse party shall be shared in accordance with Sections 8.1.4 and 8.1.5.

     8.2.4. Other than as expressly set forth to the contrary in Section 8.2.3, royalties and all
other payments hereunder shall continue unabated in accordance with the terms and conditions of
this Agreements during the pendancy (including all appeals) of any action contemplated by Section
8.2.1. through and including Section 8.2.4.

17

 

ARTICLE 9 — WARRANTIES, REPRESENTATIONS AND ACKNOWLEDGEMENTS

     9.1.1 NOVAVAX expressly warrants and represents that (a) it exclusively owns all of the
rights, title and interest in and to the Licensed Patents as defined herein existing as of the date
hereof and (b) it has the full corporate right and authority to enter into this Agreement and
to carry out the transactions contemplated herein. NOVAVAX further represents and warrants that no
academic institution, member of an academic institution, corporation, local, state or federal
government, or any other third party holds any property rights in the Licensed Patents, or to its
knowledge other Licensed Technology, that pertains to a Licensed Product existing as of the date
hereof. Further, NOVAVAX represents that the patent applications and patents of Schedule A
are all the current existing Licensed Patents reasonably relevant to the Licensed Product In the
Territory having the formulation described on Schedule B attached hereto (the
“Formulation”).

     9.1.2 NOVAVAX expressly warrants and represents that, there are no outstanding encumbrances
or agreements, either written, or to its knowledge if oral or implied, on the Licensed Technology
that are inconsistent with the obligations undertaken by NOVAVAX herein, and that it has not
granted and will not grant during the term of this Agreement or any renewal hereof, any license or
other privilege under the Licensed Technology with respect to the exclusive rights granted
hereunder for a Licensed Product in the Territory in the Field which conflicts, or which could
reasonably be expected to conflict, with the terms and conditions of this Agreement.

     9.1.3 NOVAVAX expressly warrants and represents that, to its knowledge, it has disclosed to
ESPRIT all reasonably relevant and material regarding pre-clinical and clinical studies and the
Licensed Product in its possession or control which NOVAVAX is not otherwise prohibited from
disclosing pursuant to law, regulation, order, treaty, agreement, contract or other obligation.
NOVAVAX expressly warrants and represents that, at the time of execution of this Agreement, to its
knowledge, it does not know of any third party patents or pending applications that would prohibit
NOVAVAX’s ability to obtain and enforce its patent protection for Licensed Patents existing as of
the date hereof in the Territory to the extent necessary for a Licensed Product having the Formula
which has not otherwise been cited in any patent filings by NOVAVAX with the relevant patent
offices. NOVAVAX further represents and warrants that as of the date hereof, to NOVAVAX’s
knowledge as of the Effective Date, there have been no public uses or public disclosures of the
inventions claimed in the patents and patent applications of the Licensed Patents prior to the
earliest filing date of each such respective patent or patent application.

     9.1.4 NOVAVAX expressly warrants and represents that it is not required to obtain the consent
of any third party to grant the rights granted herein to ESPRIT. NOVAVAX further expressly
warrants and represents that the rights granted herein do not conflict with any existing or pending
written agreement (or to its knowledge, any existing or pending oral or implied agreement) of
NOVAVAX with a third party pertaining to use of the Licensed Technology for a Licensed Product in
the Territory.

     9.1.5 NOVAVAX expressly warrants and represents that: a) it has not been notified in writing
of any claims of infringement from any third party with respect a Licensed Products as they
currently exist, and, to its knowledge, no third party has threatened to make any such claim; and
b) that, to its knowledge, it solely owns all of the data and results from any and all
preclinical and clinical development and testing of Licensed Products that it conducted or

18

 

authorized to have conducted prior to the Effective Date of this Agreement, and that NOVAVAX has
used reasonable efforts to disclose all of the data from such preclinical and clinical development
and testing to ESPRIT in connection with this Agreement. NOVAVAX represents that it has not
received written notice of any issued patent owned by a third party which would be infringed by the
making, using, and selling of a Licensed Product having the Formula in the countries of the
Territory utilizing the Licensed Patents of NOVAVAX as currently in existence as of the date hereof
in any in those countries of the Territory.

     9.1.6 NOVAVAX represents and warrants that, to its knowledge, it has undertaken all necessary
legal and factual steps to ensure that NOVAVAX is able to license the Licensed Technology to ESPRIT
in accordance with this Agreement to ESPRIT.

     9.1.7 NOVAVAX represents and warrants that (i) Schedule 9.1.7 attached hereto
represents a true, complete and accurate report of its sales of the Product into each distribution
channel and the Product returns it has received for the 12 month period ending September 30, 2005
broken out by month; (ii) March 31, 2005 , NOVAVAX has conducted its manufacturing and sales
activities to third parties regarding the Product in the ordinary course of business consistent
with past practice, and (iii) since March 31, 2005 through the date of hereof, NOVAVAX has not
offered any extraordinary rebates, extraordinary discounts, or any other extraordinary promotional
or marketing incentives relating to the Product and has not had sales
or returns at levels higher than those historically obtained in accordance with its ordinary
course of business consistent with past practice.

     9.2 ESPRIT expressly warrants and represents that (a) it has the full corporate right and
authority to enter into this Agreement and to carry out the transactions contemplated herein; (b)
it is not required to obtain the consent of any third party to enter into and perform its
obligations under this Agreement; (c) its entry into and performance of this Agreement do not
conflict with any existing or pending written agreement (or to its knowledge, any existing or
pending oral or implied agreement) of ESPRIT with a third party pertaining the subject matter
contained herein; (d) it is not aware of any fact or circumstance which would indicate that NOVAVAX
is in breach of any of the representations in Sections 9.1.1 through and including 9.1.2; and (e)
that the voting equity of ESPRIT is owned by each of the Private Equity Investors as set forth in
Schedule 9.2(e) attached hereto.

     9.3. THE FOREGOING WARRANTIES OF EACH PARTY ARE IN LIEU OF ANY OTHER WARRANTIES, EXPRESS OR
IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTIES OF MERCHANTABILITY OR ANY WARRANTIES OF
FITNESS FOR A PARTICULAR PURPOSE, VALIDITY, OR NON-INFRINGEMENT, ALL OF WHICH ARE HEREBY
SPECIFICALLY EXCLUDED AND DISCLAIMED.

     9.4. EXCEPT FOR THEIR RESPECTIVE OBLIGATIONS UNDER ARTICLE 11 ARISING OUT OF THIRD PARTY
CLAIMS, SUITS OR DEMANDS, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY PUNITIVE, SPECIAL,
INCIDENTAL, OR INDIRECT DAMAGES UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR
EQUITABLE THEORY ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER.

19

 

ARTICLE 10 — TERM AND TERMINATION

     10.1 The term of this Agreement shall commence on the Effective Date and shall expire upon the
expiration of the last-to-expire Licensed Patent or when terminated in accordance with any of the
provisions herein. Upon expiration of the term of this License Agreement, ESPRIT shall have a
fully paid-up license to make, have made, use and sell Licensed Products under the Licensed
Technology in the Territory.

     10.2 Termination for Breach: Upon any breach of, or default under, any material
provision of this Agreement by a Party, including, without limitation, nonpayment of amounts owed
hereunder by ESPRIT for any reason whatsoever except as specifically provided for in this
Agreement, the other Party may terminate this Agreement in whole or in part by giving ninety (90)
days’ written notice (the “Notice Period”) to the breaching Party; provided however, that the
breaching Party shall have seventy-five (75) days to cure any such breach prior to the commencement
of the Notice Period. Said notice shall become effective at the end of such Notice Period, unless
during said Notice Period the breaching Party shall cure such breach or default within the
applicable cure period. Notwithstanding anything to the contrary contained herein, payment
defaults will have a notice and cure period of five (5) days. Notwithstanding anything to the
contrary contained herein, this Agreement will terminate at the option of NOVAVAX (without notice
to ESPRIT or any other precondition on the part of NOVAVAX) upon breach by ESPRIT of any of its
obligations under the Promissory Note.

     10.3 Effect of Termination for Breach by ESPRIT: Except as otherwise expressly set
forth herein, upon termination by NOVAVAX under Section 10.2:

a) all licenses granted to ESPRIT hereunder shall cease and all such licensed rights
shall revert to NOVAVAX;

b) ESPRIT shall, and it hereby does effective only upon termination by NOVAVAX as set
forth above in 10.2, grant to NOVAVAX an exclusive (even as to ESPRIT), worldwide,
irrevocable, perpetual, fully-paid up license, under ESPRIT Improvements and ESPRIT’s
interest in the Joint Improvements, with the right to grant sublicenses, to make and have
made, import, use, sell, offer for sale, and have sold Licensed Product in the Field.

c) ESPRIT shall promptly deliver to NOVAVAX all of the following documents: (1) all
confidential information and materials related to any Licensed Product provided by NOVAVAX
pursuant to this Agreement, and (2) any New Drug Application (as defined
in 21 C.F.R. Part 314) (“NDA”), any other filing with any governmental or regulatory
authority worldwide in connection with any Licensed Product, and all related data, documents,
reports, files (including the related drug master file), filings and correspondence with any
governmental or regulatory authority, adverse event reports, clinical trial results, any
investigative new drug applications and supporting data and information (“IND”), and all other
documents or information, in whatever form, relating to the manufacture, use and sale of the
Licensed Products;

d) if ESPRIT has applied for or obtained any regulatory approvals in any country for any
Licensed Product, then ESPRIT shall, to the extent legally permissible, take all additional
action reasonably necessary to assign all of its right, title and interest in and transfer
possession and control to NOVAVAX of such applications or regulatory approvals; and

e) any regulatory filings for any Licensed Product which have been submitted in ESPRIT’s
name, subject to FDA approval, will be transferred to NOVAVAX’s name; and

20

 

     10.4 Effect of Termination for Breach by NOVAVAX: Except as otherwise expressly set
forth herein, upon termination by ESPRIT under Section 10.2:

a) ESPRIT shall be free of any obligation to make any further, unaccrued payments to NOVAVAX
relating to the terminated license pursuant to Articles 3, 4 or 5; and

b) NOVAVAX shall promptly deliver to ESPRIT all confidential information of ESPRIT,
including, confidential information relating to ESPRIT Improvements, then in NOVAVAX’s
possession and materials related to any Licensed Product provided by ESPRIT to NOVAVAX
pursuant to this Agreement.

     10.5 Termination for Bankruptcy: NOVAVAX or ESPRIT may terminate this Agreement
should the other Party commit an act of bankruptcy, be declared bankrupt, voluntarily file or have
filed against it a petition for bankruptcy or reorganization unless such petition is dismissed
within sixty (60) days of filing, enter into a procedure of winding up to dissolution or should a
trustee or receiver be appointed for its business assets or operations. All rights and licenses
granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for the
purposes of Section 365(n) of Title 11, U.S. Code (“Bankruptcy Code”) license rights to
“intellectual property” as defined under Section 101 (35A) of the Bankruptcy
Code. The parties agree that ESPRIT, as a licensee of such right, under this Agreement, shall
retain and may fully exercise all of its rights and elections under the Bankruptcy Code.

     10.6 Certain Effects of Termination; Payments and Dispute Resolution: In the event of
termination of this Agreement by NOVAVAX under Section 10.2, ESPRIT shall not be relieved of the
duty and obligation to pay in full, payments due, accrued, and unpaid at the effective date of such
termination, nor shall any such termination relieve either Party of any obligation arising
hereunder prior to such termination. Notwithstanding the foregoing, from the date either Party
notifies the other Party that it wishes to commence a proceeding in accordance with the dispute
resolution procedures set forth in Article 12 until the date such proceeding has been concluded,
the running of the time period referred to in this paragraph for curing a breach shall be suspended
with respect to the subject matter of the dispute, claim or controversy.

     10.7 Upon termination of any license granted herein, in part or in whole as to any Licensed
Product, ESPRIT shall have the right to sell off any of such Licensed Product in its inventory
provided ESPRIT pays to NOVAVAX any royalties otherwise calculated in accordance with this
Agreement.

     10.8. Survival of Provisions Upon Termination. (a) In the event of termination of
this Agreement by NOVAVAX under Section 10.2, the provisions of Section 2.4 and the provisions
listed in subsection (b) below shall survive the termination of this Agreement to the extent
provided for herein, and (b) the following provisions shall survive the termination or expiration
of this Agreement to the extent of any claims thereunder arising out of facts or circumstances
arising or existing prior to the date of such termination of expiration : Articles 6, 11, 12 and
13, and Sections 9.3, 9.4, 10.6, 10.7 and 10.8.

21

 

ARTICLE 11 — INDEMNIFICATION

     11.1 NOVAVAX and ESPRIT will each defend as the case maybe (each an “Indemnifying Party”) , at
its own expense, indemnify and hold harmless the other Party and its Affiliates from and against
any and all damages, liabilities, losses, costs, and expenses, including attorneys fees, arising
out of any claim, suit or proceeding brought against the other
Party to the extent such claim, suit, or proceeding is based upon a claim arising out of or
relating to (i) any breach or violation of, or failure to perform, any covenant or agreement made
by such indemnifying Party in this Agreement, unless waived in writing by the indemnified Party;
(ii) any breach of the representations or warranties made by such indemnifying Party in this
Agreement; or (iii) the negligence or willful misconduct of the indemnifying Party, except, under
clause (ii), to the extent arising out of the breach, violation, failure, negligence or willful
misconduct of the indemnified Party. Each Party agrees that it shall promptly notify the other in
writing of any such claim or action and give the indemnifying Party full information and assistance
in connection therewith. The indemnifying Party shall have the sole right to control the defense
of any such claim or action and the sole right to settle or compromise any such claim or action,
except that the prior written consent of the other Party shall be required in connection with any
settlement or compromise which could (i) place any obligation on or require any action of such
other Party; (ii) admit or imply any liability or wrongdoing of such other Party; or (iii)
adversely affect the goodwill or public image of such other Party. Notwithstanding the foregoing,
the indemnified Party may participate therein through counsel of its choice, but the cost of such
counsel shall be borne solely by the indemnified Party. Except as otherwise provided herein,
NOVAVAX will defend, at its own expense, indemnify and hold harmless the other ESPRIT and its
Affiliates from and against any and all damages, liabilities, losses, costs, and expenses,
including attorneys fees, arising out of any claim, suit or proceeding brought against the ESPRIT
or any such Affiliate to the extent such claim, suit, or proceeding is based upon a claim arises
out of a third party claim or suit or demand based on bodily injury or property damage resulting
from the manufacture, use or sale of Licensed Product in the Field by NOVAVAX or its Affiliates or
sublicensees pursuant to this Agreement other than in accordance with specifications as provided in
the Supply Agreement, unless such claim is due to the negligent, grossly negligent or intentional
act or omission of ESPRIT.

     11.2 In the event that any Party hereunder seeks indemnification under this Article 11, such
Party shall: (a) promptly inform the Indemnifying Party of any claim, suit or demand threatened or
filed, and (b) cooperate as requested (at the expense of the Indemnifying Party) in the defense of
such claims.

     11.3 An Indemnifying Party’s (including sublicensees) obligations under this Article 11 shall
not extend to any claims, suits or demands for liability, damages, losses, costs and
expenses arising from the Indemnified Party’s failure to comply with the terms and conditions of
this Agreement or arising from the negligence, gross negligence, intentional wrongful act or
omission of the Indemnified Party, its agents or employees.

ARTICLE 12 — ARBITRATION

     12.1 Any controversy or claim arising out of or relating to this Agreement shall be resolved
by arbitration before a panel of three arbitrators in accordance with the Commercial Arbitration
Rules of the American Arbitration Association (“AAA”) then pertaining (available at www.adr.org),
except where those rules conflict with this provision, in which case this provision controls. Any
court with jurisdiction shall enforce this clause and enter judgment on any award. The arbitrators
shall be selected within twenty Business Days from filing of a

22

 

demand for arbitration from the
AAA’s National Roster of Arbitrators pursuant to agreement or through selection procedures
administered by the AAA. Within 45 days of filing of a demand for arbitration, the parties shall
reach agreement upon and thereafter follow procedures, including limits on discovery, assuring that
the arbitration will be concluded and the award rendered within no more than eight months from
selection of the arbitrators or, failing agreement, procedures meeting such time limits will be
designed by the AAA and adhered to by the parties. The arbitration shall be held in New York, New
York, Borough of Manhattan and the arbitrators shall apply the substantive law of New York, except
that the interpretation and enforcement of this arbitration provision shall be governed by the
Federal Arbitration Act. Prior to commencement of arbitration, emergency relief is available from
any court to avoid irreparable harm. THE ARBITRATOR SHALL NOT AWARD EITHER PARTY PUNITIVE,
EXEMPLARY, MULTIPLIED OR CONSEQUENTIAL DAMAGES, OR ATTORNEYS FEES OR COSTS. Prior to commencement
of arbitration, the parties must attempt to mediate their dispute using a professional mediator
from AAA, the CPR Institute for Dispute Resolution, or like organization selected by agreement or,
absent agreement, through selection procedures administered by the AAA. Within a period of 45 days
after the request for mediation, the parties agree to convene with the mediator, with business
representatives present, for at least one session to attempt to resolve the matter. In no event
will mediation delay commencement of the arbitration for more than 45 days absent agreement of the
parties or interfere with the availability of emergency relief.

ARTICLE 13 — MISCELLANEOUS

     13.1 Any delays in or failures of performance by a Party under this Agreement shall not be
considered a breach of this Agreement if and to the extent caused by acts of God; acts, regulations
or laws of any government; strikes or other concerted acts of workers; fires; floods; explosions;
riots; wars; rebellions; and sabotage (a “Force Majeure Event”); and any time for performance
hereunder shall be extended by the actual time of delay caused by such occurrence. In the event
that a Party’s performance of payment obligations is suspended for more than one hundred and twenty
(120) days because of a Force Majeure Event, the other Party has the right to terminate this
Agreement upon written notice to the non-performing Party.

     13.2 This Agreement, or any of the rights and obligations created herein ,including but not
limited to the licenses granted under Article 2, shall not be assigned or transferred, in whole or
in part, by either Party hereto without the prior written consent of the other Party which will not
be unreasonably withheld or delayed; provided, however, that either Party may, without such
consent, assign the Agreement and its rights and obligations hereunder (A) to a wholly owned
operating Affiliate of such Party or (B) in connection with the transfer or sale of all or
substantially all of its assets to a third party so long as: (i) each Party will provide the
other Party with at least ten (10) days prior written notice thereof; and (ii) in the event of such
a transfer by NOVAVAX, any permitted assignee shall assume all obligations of its assignor under
the Agreement in a writing delivered to the other Party. Any attempted assignment or transfer of
such rights or obligations without such consent, except as provided herein, shall be void. This
Agreement shall binding upon any purchaser of all or substantially all of the assets of the either
Party, as the case may be. This Section 13.2 shall not be deemed to otherwise prohibit or
otherwise apply to a change in control of NOVAVAX (whether by merger of sale of capital stock or
otherwise) at the shareholder or Board of Director levels or otherwise.

23

 

     13.3 The waiver by a Party, whether express or implied, of any provisions of this Agreement,
or of any breach or default of a Party, shall not be construed to be a continuing waiver of such
provision, or of any succeeding breach or default or of a waiver of any other provisions of this
Agreement.

     13.4 All matters affecting the interpretation, validity, and performance of this Agreement
shall be governed by the laws of the State of New York, U.S.A., without regard to its choice or
conflict of law principles.

     13.5 Any provision hereof which is prohibited or unenforceable in any jurisdiction shall, as
to such jurisdiction, be ineffective only to the extent of such prohibition or unenforceability
without invalidating the remaining provisions hereof or affecting the validity or enforceability of
such provision in any other jurisdiction. The parties shall replace such ineffective provision for
such jurisdiction with a valid and enforceable provision which most closely approaches the NOVAVAX,
intent, and purpose of this Agreement, and in particular, the provision to be replaced.

     13.6 ESPRIT and NOVAVAX are independent contractors and shall not be deemed to be partners,
joint venturers or each other’s agents, and neither shall have the right to act on behalf of the
other except as expressly provided hereunder or otherwise expressly agreed to in writing.

     13.7 It is the mutual desire and intent of the parties to provide certainty as to their future
rights and remedies against each other by defining the extent of their mutual undertakings as
provided herein. The parties have in this Agreement incorporated all representations, warranties,
covenants, commitments and understandings on which they have relied in entering into this Agreement
and, except as provided for herein, neither Party has made any covenant or other commitment to the
other concerning its future action. Accordingly, this Agreement (together with the schedules
attached hereto (i) constitute the entire agreement and understanding between the parties with
respect to the matters contained herein, and there are no promises, representations, conditions,
provisions or terms related thereto other than those set forth in this Agreement, and (ii)
supersede all previous understandings, agreements and representations between the parties, written
or oral relating to the subject matter hereof. The parties hereto may from time to time during the
continuance of this Agreement modify, vary or alter any of the provisions of this Agreement, but
only by written agreement of all parties hereto.

     13.8 All communications, reports, payments and notices required by this Agreement shall be
addressed to the Partied(s) at their respective address(s) set forth below or to such other address
as requested by a Party by notice in writing to the other parties.

	 	 	 	 	 
	If to NOVAVAX:	 	Attention: Chief Executive Officer
	 

	 	 	 	NOVAVAX, Inc.
	 

	 	 	 	508 Lapp Road
	 

	 	 	 	Malvern, PA 19355
	 
	 	 	 	 
	 

	 	With a copy to:
	 	Ropes & Gray LLP
	 

	 	 	 	45 Rockefeller Plaza
	 

	 	 	 	New York, NY 10111
	 

	 	 	 	Attention: Sanford B. Kaynor, Jr.

24

 

	 	 	 	 	 
	If to ESPRIT:	 	Attention: Chief Executive Officer
	 

	 	 	 	Esprit Pharma, Inc.
	 

	 	 	 	Two Tower Blvd.
	 

	 	 	 	East Brunswick, NJ 08816
	 
	 	 	 	 
	 

	 	With a copy to:
	 	Steven M. Bosacki, General Counsel
	 

	 	 	 	Esprit Pharma, Inc.
	 

	 	 	 	Two Tower Blvd.
	 

	 	 	 	East Brunswick, NJ 08816

     All such notices, reports, payments and communications shall be made by First Class mail;
postage prepaid, and shall be considered made as of the date of deposit with the United States Post
Office.

     13.9 This Agreement may not be amended or modified unless in writing executed by both parties
hereto. Except as otherwise expressly set forth herein, neither party will have any rights of
setoff or to withhold the performance of any obligation (including with respect to any payment
otherwise required to be made) hereunder.

     13.10. Unless otherwise expressly provided for herein (i) financial and accounting terms will
have the meaning ascribed to such terms in accordance with GAAP, (ii) the word, “including”, will
mean “including but not limited to” and the word “day” will mean “calendar day”, (iii) references
to the singular will include the plural and vice versa, (iv) the use of any
pronoun will include the neuter and both genders, and (v) references to Sections, Articles,
Schedules and Exhibits will be references to Sections, Articles, Schedules and Exhibits to this
Agreement and the word, “herein” and words of similar import will be construed to refer to this
Agreement, (vi) the word “knowledge” will mean actual knowledge after reasonably diligent inquiry
of executive officers of the relevant entity, and (vii) headings and titles of Sections and
Articles herein will be construed to be descriptive only and without any substantive or
interpretive effect.

     13.11 If at any time during the term of this Agreement and prior to *****, NOVAVAX receives a
bona fide proposal from a third party to enter into an exclusive license agreement to market a
product containing ***** in NOVAVAX’s ***** for the treatment of *****. NOVAVAX shall promptly
notify ESPRIT in writing. ESPRIT may, but shall not be obligated to deliver to NOVAVAX within in
***** (*****) days of receipt of such notice, a letter stating that ESPRIT wishes to enter into an
exclusive license for any of the products herein as the case may be, on substantially the same
terms and conditions received in its most favorable third party proposal. The parties hereto agree
to diligently negotiate in good faith to complete the transaction contemplated herein. In the event
the parties are not able to consummate an agreement ***** (*****) days of receipt of such notice,
NOVAVAX shall be entitled to negotiate a transaction with respect to the foregoing product on terms
acceptable to NOVAVAX

 

			
	*	 	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.

25

 

ARTICLE 14 — TAXES

     14.1 ESPRIT will make all payments to NOVAVAX under this Agreement without deduction or
withholding for taxes except to the extent that any such deduction or withholding is required by
law in effect at the time of payment.

     14.2 Any tax required to be withheld on amounts payable under this Agreement will promptly be
paid by ESPRIT on behalf of NOVAVAX to the appropriate governmental authority, and ESPRIT will
furnish NOVAVAX with proof of payment of such tax.

     14.3 ESPRIT and NOVAVAX will cooperate with respect to all documentation required by any
taxing authority or reasonably requested by ESPRIT to secure a reduction in the rate of applicable
withholding taxes.

26

 

	 	 	 	 	 	 	 	 	 
	NOVAVAX, INC.	 	 	 	ESPRIT PHARMA, INC.
	 
	 	 	 	 	 	 	 	 
	By:

	 	 	 	 	 	By:	 	 
	 

	 	 
	 	 	 	 	 	 
	 

	 	Name:
	 	 	 	 	 	Name:
	 	 	Title: President and Chief Executive Officer	 	 	 	Title:
	Date:

	 	 	 	 	 	Date:	 	 
	 

	 	 
	 	 	 	 	 	 

27

 

LICENSE AGREEMENT

Schedule A — Patents and Patent Applications

	 	 	 	 	 	 	 	 	 	 	 
	Country	 	Status	 	Application No.	 	Patent No.	 	Issue Date	 	Expiration
	United States
	 	Granted	 	08/380942	 	5629021	 	05/13/1997	 	01/31/2015
	Mexico
	 	Granted	 	975663	 	198438	 	09/04/2000	 	01/29/2016
	Canada
	 	Granted	 	2211262	 	2211262	 	08/30/2005	 	01/29/2016

28

 

LICENSE AGREEMENT

Schedule B — Formulation For Existing Estrasorb®Licensed Product

Formulation (NOVAVAX-033/2)

	 	 	 
	Ingredient Description	 	Percent w/w
	17 b -Estradiol USP/Ph. Eur.
	 	*****
	Soybean Oil USP
	 	*****
	Polysorbate 80 NF
	 	*****
	190 Proof Ethyl Alcohol USP
	 	*****
	Purified Water USP
	 	*****

 

			
	*	 	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.

29

 

LICENSE AGREEMENT

Schedule 1 — Trademarks

	 	 	 	 	 	 	 	 	 	 	 
	 	 	Application No.	 	Registration	 	Status /	 	Date
	ESTRASORB

	 	75/833622
	 	 	2784534	 	 	Registered
	 	18-Nov-2003

	 	 	 	 	 
	 

	 	Class 5	 	 
	 	 	Goods: pharmaceuticals, namely topical hormone preparations
	 

	 	 	 	International Class: 005
	 

	 	 	 	First Use Date: 2003-03-03
	 

	 	 	 	First Use in Commerce Date: 2003-03-03
	 
	 	 	 	 
	 

	 	 	 	Basis: 1(a)

www.estrasorb.com 

30

 

LICENSE AGREEMENT

Schedule 9.1.7 — Product Sales and Returns

Novavax, Inc.

Estrasorb Sales by Month

	 	 	 	 	 	 	 	 	 	 
	 	 	 	Gross Sales	 	Returns
	 	 	 	Units	 	Dollars	 	Units	 	Dollars
	 	 	 	 	 	$	 	 	 	 
	 

	Oct-04
	 	*****
	 	*****
	 	*****
	 	*****
	 

	Nov-04
	 	*****
	 	*****	 	 	 	 
	 

	Dec-05
	 	*****
	 	*****	 	 	 	 
	 

	Jan-05
	 	*****
	 	*****	 	 	 	 
	 

	Feb-05
	 	*****
	 	*****	 	 	 	 
	 

	Mar-05
	 	*****
	 	*****	 	 	 	 
	 

	Apr-05
	 	*****
	 	*****
	 	*****
	 	*****
	 

	May-05
	 	*****
	 	*****
	 	*****
	 	*****
	 

	Jun-05
	 	*****
	 	*****	 	 	 	 
	 

	Jul-05
	 	*****
	 	*****	 	 	 	 
	 

	Aug-05
	 	*****
	 	*****
	 	*****
	 	*****
	 

	Sep-05
	 	*****
	 	*****	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 
	Totals

	 	 	*****
	 	*****
	 	 	 	*****

 

			
	*	 	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.

31

 

LICENSE AGREEMENT

Schedule 9.2(e) — Voting Equity of ESPRIT

	 	 	 
	 	 	Fully Diluted
	 	 	Voting
	 	 	Equity
	Private Equity Investor	 	Percentage
	*****

	 	*****%
	*****

	 	*****%
	*****

	 	*****%

 

			
	*	 	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.

32

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}]]